COMBINATION FORMULATIONS OF COMBINUridine

The FDC formulation of cedaruridine and enteric-coated azacitidine mini-tablets addresses low oral bioavailability by enhancing absorption and compliance in cancer treatment.

CN119072303APending Publication Date: 2024-12-03TAIHO PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034664.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-27
Filing Date
2023-02-22
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing cytidine analog drugs like azacitidine have low oral bioavailability due to degradation by cytidine deaminase and chemical instability in the acidic gastric environment, necessitating improved formulations to enhance absorption and reduce resistance in cancer treatment.

Method used

A fixed dose combination (FDC) formulation with immediate release of cedaruridine and delayed, enteric release of azacitidine, utilizing modified release mini-tablets and enteric coatings to optimize azacitidine bioavailability outside the stomach.

Benefits of technology

Enhances azacitidine bioavailability and reduces variability in drug exposure, improving cancer treatment efficacy by increasing absorption and compliance with reduced pill burden.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072303A_ABST
    Figure CN119072303A_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to a pharmaceutical dosage form comprising azacitidine (azacitidine) and cedazuridine (cedrine). The present disclosure relates to a pharmaceutical dosage form comprising azacitidine (azacitidine) and cedazuridine (cedrine).
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] Pursuant to 35 U.S.C. §119(e), this application claims the benefit of U.S. Provisional Application No. 63 / 312,712 filed on February 22, 2022, U.S. Provisional Application No. 63 / 312,714 filed on February 22, 2022, and U.S. Provisional Application No. 63 / 377,312 filed on September 27, 2022, the entire contents of which are hereby incorporated by reference. Technical Field

[0002] The present disclosure relates to a combination preparation comprising azacitidine or a pharmaceutically acceptable salt thereof, and cedazuridine or a pharmaceutically acceptable salt thereof. Background Art

[0003] Cancer is a global health problem; the World Health Organization estimates that in 2020, cancer will account for nearly 10 million deaths worldwide. Each cancer type requires a specific treatment regimen and sometimes cancers acquire resistance to certain treatments. Combination therapies can reduce the development of resistance and improve overall survival (OS) and / or delay disease progression (progression-free survival (PFS)).

[0004] It has been shown that cancers that acquire resistance to cytidine analog drugs often overexpress cytidine deaminase (CDA) (Leuk. Res. 1990, 14, 751-754). Leukemia cells that highly express CDA can become resistant to cytosine antimetabolites and thus limit the antitumor activity of such therapies (Biochem. Pharmacol. 1993, 45, 1857-1861). CDA inhibitors can be used in combination chemotherapy regimens involving cytidine analog drugs.

[0005] It has been found that when azacitidine, a cytidine analog drug, was orally administered (8 mg / kg) to repeatedly bled baboons (PCV less than 20%), fetal hemoglobin levels (Hb F) did not increase, indicating very low oral bioavailability (DeSimone et al. (1985) Amer. J. of Hem. 18:283-288). It is speculated that the poor bioavailability of cytidine analogs is due to degradation of cytidine analogs by cytidine deaminase and their inherent chemical instability in the acidic gastric environment. To date, only one orally administered azacitidine product has been approved, and it provides an average oral bioavailability of about 11% relative to subcutaneous administration. There is a need for formulations of cytidine analogs such as azacitidine that can increase the bioavailability of azacitidine.

[0006] Fixed dose combination (FDC) formulations are also desirable because they can reduce the pill burden for patients undergoing combination chemotherapy and improve patient compliance with treatment regimens.There is a need for FDC formulations comprising a combination of a cytidine analog and a CDA inhibitor. Summary of the invention

[0007] It has been reported that certain cytidine analogs (e.g., 5-azacytidine) are acid labile and enteric coatings have been introduced for such drugs. See, e.g., US2004 / 0162263. It has been found that enteric release of azacitidine increases the bioavailability of azacitidine and co-administration with cedaruridine, a CDA inhibitor, further increases the bioavailability of azacitidine. Gastric release of cedaruridine further enhances the effect of increasing the absorption of azacitidine and can reduce the amount of azacitidine taken orally. The present disclosure provides a fixed dose combination (FDC) formulation that enables immediate release of cedaruridine and delayed, enteric release of azacitidine, thereby achieving the desired degree of azacitidine bioavailability with a reduced amount of azacitidine.

[0008] The present disclosure provides, in one embodiment, a pharmaceutical dosage form comprising chiduridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the chiduridine is formulated for immediate release; at least a portion of the azacitidine is formulated for modified release and is provided as an enteric-coated mini-tablet or pellet. In some embodiments, the chiduridine is formulated for immediate release. In some embodiments, substantially all of the azacitidine is structured to be released outside the stomach.

[0009] Provided herein is a pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release; and the azacitidine is formulated as a modified release mini-tablet with an enteric coating. In some embodiments, the cedaruridine is provided as an uncoated mini-tablet, pellet, or powder.

[0010] Provided herein is a capsule comprising one or more azacitidine mini-tablets formulated for modified release and immediate-release cedaruridine in the form of an uncoated powder or mini-tablet. The azacitidine mini-tablet comprises azacitidine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable excipient, and an enteric coating. The immediate-release cedaruridine comprises cedaruridine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0011] Provided herein is a method of treating cancer in a patient, comprising administering a pharmaceutical dosage form. Also provided herein is a pharmaceutical dosage form for treating cancer, or for manufacturing a medicament for treating cancer. Also provided herein is a use of a pharmaceutical dosage form for treating cancer, or for manufacturing a medicament for treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Shown is the dissolution release profile of azacitidine at pH 6.8 from a coated FDC tablet comprising cedaruridine and azacitidine with 12% or 15% (coating) weight gain according to one embodiment.

[0013] Figure 2 Shown is the dissolution release profile of azacitidine from capsules containing uncoated or coated azacitidine mini-tablets at pH 6.8 according to one embodiment.

[0014] Figure 3 Shown is the dissolution profile of azacitidine from a capsule comprising azacitidine mini-tablets at pH 6.8, wherein 50% of azacitidine (10 mg) is uncoated (immediate release) and 50% of azacitidine (10 mg) is coated (delayed release), according to one embodiment.

[0015] Figure 4 The dissolution profile of azacitidine from a capsule comprising azacitidine mini-tablets at pH 6.8 according to one embodiment is shown, wherein the uncoated and coated azacitidine mini-tablets are in a ratio of 1:1 or 1:2.

[0016] Figure 5 Shown is the dissolution profile of azacitidine at pH 6.8 from capsules containing azacitidine mini-tablets having a 15% or 20% (coating) weight gain according to one embodiment.

[0017] Figure 6 The dissolution release profile of azacitidine from a capsule (including an inner granule layer and an outer granule layer) containing uncoated cedaruridine mini-tablets and 75:25 and 80:20 ethylcellulose-coated azacitidine mini-tablets at pH 6.8 according to one embodiment is shown. (wg refers to the weight gain of the coating).

[0018] Figure 7 Shown is dissolution data for coated azacitidine mini-tablets from pH 1 to pH 6.8 according to one embodiment.

[0019] Figure 8 Shown is dissolution data for coated azacitidine mini-tablets from pH 1 to pH 6.8 according to one embodiment.

[0020] Fig. 9 The dissolution profile of a real-time release cedaruridine mini-tablet from pH 1 to pH 6.8 according to one embodiment is shown.

[0021] Fig.10 Shown is the dissolution profile of a coated azacitidine mini-tablet from pH 1 to pH 6.8 according to one embodiment.

[0022] Fig.11 Shown are the dissolution profiles of coated azacitidine mini-tablets at pH 2.3, 3.0, 4.5, 5.2, 5.5, and 6.0 according to one embodiment.

[0023] Fig.12 Shown are the mean azacitidine concentration-time profiles for the three groups on Days 1 and 2 of the monkey pharmacokinetic (PK) study.

[0024] Fig.13 Shown are the mean cedaruridine concentration-time profiles for the three groups on days 1 and 2 in a monkey pharmacokinetic (PK) study.

[0025] Fig.14 Shown are the mean azacitidine concentration-time profiles for the three groups on Days 1 and 2 of the monkey pharmacokinetic (PK) study.

[0026] Fig.15 Shown are the mean azacitidine concentration profiles for 15% weight gain coated mini-tablets at 80 / 20 ratio from the Part 1 PK study.

[0027] Fig.16 Shown are the mean azacitidine concentration profiles for 20% weight gain coated mini-tablets at 75 / 25 ratio from the Part 2 PK study.

[0028] Fig.17 Showed 5.3% in monkey PK studies Mean azacitidine concentration profile for coated azacitidine mini-tablets.

[0029] Fig.18A Shown is the dissolution profile of cedaruridine from a capsule according to one embodiment.

[0030] Fig.18B Shown is the dissolution profile of azacitidine from a capsule according to one embodiment.

[0031] Fig.19 Shown is the plasma exposure of cedaruridine from a pharmacokinetic (PK) study in monkeys.

[0032] Fig. 20 Shown is the plasma exposure of azacitidine from the PK study in monkeys.

[0033] It will be appreciated that some or all of the figures are schematic for illustrative purposes. DETAILED DESCRIPTION

[0034] Efforts to increase the bioavailability of cytosine analogs have been described, for example, in U.S. Patent Application Publication No. 2004 / 0162263 (Sands et al.). In this publication, delivery of decitabine in an enteric coated formulation is disclosed so that the drug is preferentially absorbed in the upper region of the small intestine, such as the jejunum. U.S. Patent Application Publication No. 2008 / 0057086 (Pharmion) describes delivery of azacitidine to the upper region of the large intestine. The bioavailability of an 80 mg oral dose in three patients was improved by 6.3%, 24%, and 22% relative to the SC dose. The T of the three subjects who received the 80 mg dose was 2.4%, 1.2%, and 2.1%, respectively. max Occurs at 1.5, 2.0 and 1.0 hours after administration.

[0035] The stomach is an area of ​​high acidity (approximately pH 1 to 3). Specific glands and organs that empty into the small intestine raise the pH of the material leaving the stomach to about pH 6.0 to 6.5. The large intestine and colon are generally at about pH 6.4 to 7.0. The transit time through the small intestine is about three hours. In contrast, the transit time through the large intestine is about 35 hours. Gastric acid is thought to degrade azacitidine. In addition, longer transit times in the large intestine can lead to higher enzymatic degradation of azacitidine and subsequent poor bioavailability. Therefore, it is desirable to release and absorb azacitidine outside the stomach to achieve higher bioavailability. In some embodiments, co-administration of cyduridine (a cytidine deaminase inhibitor) can reduce the enzymatic degradation of azacitidine. In some embodiments, releasing azacitidine at a pH of about 6.8 in the proximal region of the small intestine can increase the absorption of azacitidine.

[0036] In some embodiments, the compositions described herein enhance the bioavailability of azacitidine regardless of the site of release of azacitidine in the intestine. In some such embodiments, cedaruridine is co-administered and / or co-formulated with azacitidine. In addition, the site of release of cedaruridine affects the enhancement of the bioavailability of azacitidine. In some embodiments, when cedaruridine and azacitidine are administered in a fixed dose composition described herein, the immediate release of cedaruridine in the stomach enhances the bioavailability of azacitidine to a greater extent than the delayed release of cedaruridine.

[0037] Azacitidine bioavailability is further enhanced by the modified release dosage forms of azacitidine described herein. In addition, the variability of drug exposure is reduced. In some embodiments, the azacitidine is released at pH>3. In some embodiments, the azacitidine is released outside the stomach. In some embodiments, enhanced absorption and / or bioavailability of azacitidine can occur when cedaruridine is co-administered and released prior to the release of azacitidine. For example, cedaruridine can be released in the stomach and azacitidine can be released outside the stomach, thereby improving the absorption and / or bioavailability of azacitidine. definition

[0038] The following description sets forth exemplary embodiments of the present technology. However, it should be appreciated that such description is not intended as a limitation on the scope of the present disclosure but is provided as a description of exemplary embodiments.

[0039] As used in this specification, the following words, phrases and symbols are generally intended to have the meanings set forth below, unless otherwise indicated by the context in which they are used.

[0040] References herein to "about" a certain value or parameter include (and describe) embodiments directed to the value or parameter itself. In certain embodiments, the term "about" includes a specified amount ± 10%. In other embodiments, the term "about" includes a specified amount ± 5%. In certain other embodiments, the term "about" includes a specified amount ± 1%. The term "about X" includes a description of "X".

[0041] The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a dosage form" includes a plurality of such dosage forms.

[0042] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0043] The term "polymer" refers to a chemical compound or mixture of compounds composed of repeating structural units produced by the process of polymerization. Suitable polymers that can be used in the present dosage forms are described throughout.

[0044] "Blend" refers to a solid form in which an active agent is mixed with additional excipients (including but not limited to bulk fillers, glidants and / or lubricants). The ratio of active agent to excipient can vary and depends on the nature of the active agent. Typically, the blend is in the form of a powder.

[0045] In some embodiments, a "granule" is a particle having an irregular shape. In some embodiments, a "granule" is a solid agglomerate of powder particles.

[0046] "Pellets" are solid masses comprising active agents and / or additional fillers. Pellets include, but are not limited to, discs, beads, prolate spheroids, oblate spheroids, spheres, cylinders, and the like. "Tablets" are round compressed solid dosage forms having a diameter less than that of tablets (i.e., equal to or less than 6 mm in diameter), compressed solid masses comprising active agents and / or additional fillers. In some embodiments, "pellets" include "tablets" or vice versa. In some embodiments, "pellets" and "tablets" can be used interchangeably. "Pellets" and / or "tablets" can refer to subunits of a unit pharmaceutical dosage form (such as a capsule or tablet).

[0047] In some embodiments, a "tablet" is a compressed solid block cylinder, and typically, the height of the cylinder is less than or equal to the diameter of the cylinder. In some embodiments, a "tablet" may refer to a pharmaceutical dosage form, which may contain one or more subunits, such as pellets, mini-tablets, granules, or powders.

[0048] "FDC" or "fixed dose combination" refers to a pharmaceutical dosage form containing two or more drugs contained in a single dosage form, such as a capsule or tablet.

[0049] "Modified release" refers to drug release that occurs substantially outside the stomach. In some embodiments, the modified release is insensitive to pH changes that occur outside the stomach. By way of example only, a hydroxypropyl methylcellulose coating is substantially insensitive to pH changes outside the stomach and the modified release can occur at any pH above the pH in the stomach. In some embodiments, the modified release is pH sensitive and release at the desired pH is achieved by using an appropriate coating. By way of example only, a polymethacrylate polymer coating (such as ) is tunable and can be modified to occur at pH>5.5 (targeting the duodenum); at pH 6 to 7 (jejunum); or at pH>7 (ileum and colon).

[0050] "Enteric release" refers to releasing the drug substantially in the intestine to prevent the drug from being degraded due to acid-catalyzed hydrolysis in the stomach. "Enteric coating" or "enteric coating" refers to a coating that allows the drug to be released substantially in the intestine. In some embodiments, enteric release is "delayed release" or "timed release", which is pH sensitive and occurs at pH>5.5 (targeting the duodenum); at pH 6 to 7 (jejunum); or at pH>7 (ileum and colon). "Delayed release coating" or "delayed release coating" refers to a coating that is sensitive to pH changes in the intestine and the release of the drug is delayed until the target pH environment is available. In some embodiments, the enteric coating is a delayed release coating.

[0051] "Seal coating" refers to a coating that is layered onto the uncoated pellets before coating them with an enteric coating. The seal coating forms an intermediate layer and prevents interaction between the core containing the active agent and the enteric coating. In some embodiments, the seal coating comprises a polymer that allows for intermediate release.

[0052] As used herein, the term "% w / w" of a component refers to the weight of the component based on the total weight of the dosage form in which it is included. For example, if component A is present in a 100 mg dosage form at 50% w / w, then component A is present in an amount of 50 mg.

[0053] The term "volume filler" refers to a chemical compound used to dilute the compound of interest. Volume fillers can also be used to stabilize compounds. Non-limiting examples of volume fillers include starch, sugar, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, microcrystalline cellulose, calcium carbonate or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, mannitol, microcrystalline cellulose and tricalcium phosphate.

[0054] The term "glidant" refers to an excipient used to promote powder flow by reducing interparticle friction and cohesion. Glidants can improve flow properties during tablet compression and produce an anti-caking effect. Non-limiting examples of glidants include colloidal silicon dioxide, talc, fumed silica, starch, starch derivatives, magnesium carbonate, and bentonite. Glidants are often used in combination with lubricants.

[0055] The term "lubricant" refers to an excipient added to a powder blend to prevent the compacted powder mass from sticking to the equipment during processing. It helps the compacted solid mass to pop out of the die and can improve powder flow. Non-limiting examples of lubricants include magnesium stearate, stearic acid, silicon dioxide, fats, calcium stearate, polyethylene glycol, sodium stearyl fumarate, talc, and solubilizers (such as fatty acids, including lauric acid, oleic acid, and C8 / C10 fatty acids).

[0056] "Substantially" all of the azacitidine means greater than 70%; or greater than 75%; or greater than 80%; or greater than 85%; or greater than 90%; or greater than 95%; or greater than 99% of the azacitidine. "Substantially" releasing the drug outside the stomach means greater than 70%; or greater than 75%; or greater than 80%; or greater than 85%; or greater than 90%; or greater than 95%; or greater than 99% of the drug is released outside the stomach.

[0057] "pH changes in the intestine" refers to changes in pH in the intestinal lumen from the stomach to the rectum. For example, the pH in the duodenum is about 5.5 or higher; the pH in the jejunum is about 6 to 7; the pH in the ileum and colon is about 7 or higher; the pH in the cecum is about 5.7; and the pH in the rectum is about 6.7.

[0058] A "pH-insensitive" enteric coating refers to a coating that allows drug release to occur at any pH outside the stomach. A "pH-sensitive" enteric coating allows drug release at a target pH (eg, a target area within the intestinal lumen).

[0059] As used herein, "hydroxypropyl methylcellulose" is used interchangeably with "HPMC" and / or "hydroxypropyl methylcellulose." "HPMC" includes hydroxypropyl methylcellulose acetate succinate (HPMCAS) and / or commercially available HPMCAS grades.

[0060] As used herein, Refers to the category of copolymers based on polymethacrylates. It includes anionic, cationic and / or neutral copolymers based on methacrylic acid and methacrylic acid / acrylates or their derivatives. Various grades of polymers are commercially available, including but not limited to L 30D-55, FS 30D and FL 30D-55. Anionic L dissolves at pH>6 and is used for enteric coating, while soluble at pH>7 S for colon targeting. S and The combination of L can provide drug release at pH < 7. RL and RS are water-insoluble but swellable / permeable polymers suitable for sustained-release film coating applications.

[0061] "Cedaruridine" includes diastereomers of cedaruridine and is not limited to the isomers depicted herein.

[0062] "Amino acid salt" in the context of a buffer refers to a buffer salt comprising one or more amino acids, such as histidine, glycine, or any other amino acid known to those skilled in the art. Amino acids contain a positively charged amino group and a negatively charged carboxyl group. The charged regions of these molecules can bind hydrogen and hydroxyl ions and thus act as a buffer.

[0063] In many cases, the compounds of the present disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0064] Pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs and prodrugs of the compounds described herein are also provided. "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.

[0065] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of a given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts with inorganic acids and salts with organic acids. In addition, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt (particularly a pharmaceutically acceptable addition salt) can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, for example, salts of acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic bases and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of NH3, or primary, secondary, or tertiary amines, such as those derived from N-containing heterocycles, N-containing heteroaryls, or from formula N(R N )3 amine (such as HN + (R N )3 or (alkyl) N + (R N )3) wherein each R N is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted, such as with one or more (e.g., 1 to 5 or 1 to 3) substituents (e.g., halogen, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or haloalkoxy). Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0066] "Alkyl" refers to a straight or branched saturated hydrocarbon chain. As used herein, an alkyl group has 1 to 20 carbon atoms (i.e., C 1-20 Alkyl), 1 to 8 carbon atoms (i.e. C 1-8 Alkyl), 1 to 6 carbon atoms (i.e. C 1-6 alkyl), or 1 to 4 carbon atoms (i.e. C 1-4 Alkyl). Examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-methyl, and 3-methylpentyl. When an alkyl residue having a particular number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons are contemplated; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3); and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0067] "Alkenyl" refers to a group having at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e. C 2-4 Examples of the alkenyl group include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0068] "Alkynyl" refers to a group having at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C 2-20 Alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl), or 2 to 4 carbon atoms (i.e. C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0069] “Alkoxy” refers to “alkyl-O—.” Examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0070] "Haloalkyl" refers to an alkyl group as defined above and "haloalkoxy" refers to an alkoxy group as defined above wherein one or more hydrogen atoms of the alkyl or alkoxy group are replaced by a halogen.

[0071] As used herein, the term "amino" refers to a group of the formula -N(RN )2 amine, wherein each R N are independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted, such as with one or more (e.g., 1 to 5 or 1 to 3) substituents (e.g., halogen, cyano, hydroxy, -NH2, -NH(alkyl), -N(alkyl)2, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or haloalkoxy).

[0072] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, an aryl group has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 12 ring carbon atoms (i.e., C 6-12 aryl), or 6 to 10 ring carbon atoms (i.e. C 6-10 The term "aryl" refers to a group consisting of a phenyl group, a naphthyl group, a fluorenyl group, and an anthracenyl group. However, an aryl group does not include or overlap in any way with a heteroaryl group as defined below. If one or more aryl groups are fused to a heteroaryl group, the resulting ring system is a heteroaryl group. If one or more aryl groups are fused to a heterocyclyl group, the resulting ring system is a heterocyclyl group.

[0073] "Cycloalkyl" refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings, including fused, bridged and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, a cycloalkyl group has 3 to 20 ring carbon atoms (i.e., C 3-20 Cycloalkyl), 3 to 12 ring carbon atoms (i.e. C 3-12 Cycloalkyl), 3 to 10 ring carbon atoms (i.e. C 3-10 Cycloalkyl), 3 to 8 ring carbon atoms (i.e. C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e. C 3-6 Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0074] "Halogen" or "halo" includes fluorine, chlorine, bromine and iodine.

[0075] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, wherein one or more ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl group includes 1 to 20 ring carbon atoms (i.e., C 1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C 3-12 heteroaryl), or 3 to 8 ring carbon atoms (i.e., C 3-8heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, the heteroatoms being independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl include pyrimidinyl, purinyl, pyridinyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolyl, isoquinolyl, benzo[b]thienyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridine, wherein the heteroaryl may be bound via any ring of the fused system. Any aromatic ring containing at least one heteroatom with a single or polycyclic fused ring is considered a heteroaryl, regardless of connection to the rest of the molecule (i.e., through any of the fused rings). Heteroaryl does not contain or overlap with an aryl as defined above.

[0076] "Heterocyclyl" refers to a saturated or unsaturated cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The term "heterocyclyl" includes heterocycloalkenyl (i.e., a heterocyclyl having at least one double bond), bridged heterocyclyl, fused heterocyclyl and spiro heterocyclyl. The heterocyclyl group may be a single ring or multiple rings, wherein the multiple rings may be fused, bridged or spiro. Any non-aromatic ring containing at least one heteroatom is considered to be a heterocyclyl, regardless of connection (i.e., it may be bound by a carbon atom or a heteroatom). In addition, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of connection to the rest of the molecule. As used herein, a heterocyclyl group has 2 to 20 ring carbon atoms (i.e., C 2-20 heterocyclic group), 2 to 12 ring carbon atoms (i.e., C 2-12 heterocyclic group), 2 to 10 ring carbon atoms (i.e., C 2-10 heterocyclic group), 2 to 8 ring carbon atoms (i.e., C 2-8 heterocyclic group), 3 to 12 ring carbon atoms (i.e., C 3-12 heterocyclic group), 3 to 8 ring carbon atoms (i.e., C 3-8 heterocyclic group), or 3 to 6 ring carbon atoms (i.e. C 3-6heterocyclic radical); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, the heteroatom being independently selected from nitrogen, sulfur or oxygen. Examples of heterocyclic radicals include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl and morpholinyl. As used herein, the term "bridged heterocyclic radical" refers to a four- to ten-membered cyclic moiety connected to one or more (e.g., 1 or 2) four- to ten-membered cyclic moieties having at least one heteroatom at two non-adjacent atoms of a heterocyclic radical, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. As used herein, bridged heterocyclic radicals include bicyclic and tricyclic systems. As also used herein, the term "spiroheterocyclyl" refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional rings, wherein the one or more additional rings are three- to ten-membered cycloalkyl or three- to ten-membered heterocyclyl, wherein a single atom of the one or more additional rings is also an atom of the three- to ten-membered heterocyclyl. Examples of spiroheterocyclyl rings include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, wherein the heterocyclyl may be bound via any ring of the fused system.

[0077] "Hydroxy" or "hydroxyl" refers to the group -OH.

[0078] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, they are contemplated for use in the therapeutic composition. Supplementary active ingredients may also be incorporated into the composition.

[0079] "Solvates" are formed by the interaction of a solvent with a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.

[0080] As referred to herein, "medicaments" or "pharmaceuticals" can be prepared by conventional processes (comprising a combination of one or more compounds according to the present disclosure and a pharmaceutically acceptable carrier). For example, in the context of the present disclosure, the medicaments may include azacitidine and cedaruridine. Combination of Azacitidine and Chiduraidine

[0081] In one embodiment, provided herein is a pharmaceutical dosage form or composition comprising azacitidine or a pharmaceutically acceptable salt thereof. The pharmaceutical dosage form or composition may further include a CDA inhibitor (such as cedaruridine or a pharmaceutically acceptable salt thereof) to enhance the bioavailability of azacitidine.

[0082] In one embodiment, provided herein is a fixed dose combination, pharmaceutical dosage form or composition comprising cedaurin or a pharmaceutically acceptable salt thereof and azacitidine or a pharmaceutically acceptable salt thereof. The chemical structures of both cedaruridine and azacitidine are shown below. Release profile of azacitidine

[0083] It has been found that enteric release of azacitidine in the intestine is more favorable for the bioavailability of azacitidine than release in the stomach, and at least a portion of the azacitidine in a pharmaceutical dosage form or composition can be formulated so that it is released in the intestine rather than in the stomach. In one embodiment, the fixed dose combination, pharmaceutical dosage form or composition comprises azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release. For example, about 5%, 10%, 15%, 20%, 25%, 30%, 33.3%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the azacitidine (by weight) can be formulated for modified release. In some embodiments, about 1 / 3 or 2 / 3 of the azacitidine (by weight based on the total weight of azacitidine in the tablet or capsule) may be formulated for modified release. In some embodiments, no azacitidine is formulated for immediate release (e.g., release in the stomach) and the azacitidine is formulated for modified release. In some such embodiments, the azacitidine formulated for modified release is coated. In some embodiments, the coated azacitidine is in the form of pellets. In some embodiments, the coated azacitidine is in the form of mini-tablets.

[0084] In some embodiments of the pharmaceutical dosage form, the portion of azacitidine formulated for modified release is formulated for enteric release. In some such embodiments, the portion of azacitidine formulated for modified release is formulated for enteric release, which is a delayed release at a targeted pH (e.g., pH of the duodenum, jejunum, ileum, or colon). In some embodiments of the pharmaceutical dosage form, the portion of azacitidine formulated for immediate release is provided as an uncoated mini-tablet or pellet. Such uncoated mini-tablets or pellets form a core that is optionally coated with a release-modifying coating. In some embodiments of the pharmaceutical dosage form, the portion of azacitidine formulated for modified release is provided as an enteric-coated mini-tablet or pellet. In some embodiments, the enteric coating or release-modifying coating is pH sensitive.

[0085] In some embodiments, at least a portion of the azacitidine is formulated for immediate release (e.g., release in the stomach). For example, about 5%, 10%, 15%, 20%, 25%, 30%, 33.3%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the azacitidine (by weight) may be formulated for immediate release. In some embodiments, about 1 / 3 or 2 / 3 of the azacitidine (by weight) may be formulated for immediate release. In some such embodiments, the azacitidine formulated for immediate release is uncoated. In some embodiments, the uncoated azacitidine is a powder. In some embodiments, the uncoated azacitidine is a blend (e.g., a powder blend). In some embodiments, the uncoated azacitidine is in the form of granules. In some embodiments, the uncoated azacitidine is in the form of pellets. In some embodiments, the uncoated azacitidine is in the form of mini-tablets.

[0086] In some embodiments of the pharmaceutical dosage form, about 0% to about 60% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 100% to about 50% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 0% to about 70% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 100% to about 30% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 10% to about 65% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 90% to about 35% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 20% to about 60% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 80% to about 40% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 30% to about 65% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 70% to about 35% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 30% to about 60% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 70% to about 40% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet. In some embodiments of the pharmaceutical dosage form, about 37% to about 60% of the azacitidine is provided as an uncoated mini-tablet or pellet and about 40% to about 63% of the azacitidine is provided as a modified release uncoated mini-tablet or pellet.

[0087] In some embodiments of the pharmaceutical dosage form, all of the azacitidine is formulated for modified release. In some embodiments of the pharmaceutical dosage form, no azacitidine is formulated for immediate release. In some embodiments of the pharmaceutical dosage form, substantially all of the azacitidine is formulated for modified release. In some such embodiments, substantially all of the azacitidine is released outside the stomach (e.g., in the intestine). Release curve of sidauridine

[0088] Although cedaruridine enhances the bioavailability of azacitidine, the release position of cedaruridine affects the enhancement of the bioavailability of azacitidine, and it has been found that the real-time release of cedaruridine (release in the stomach) further contributes to the enhancement of the bioavailability of azacitidine.

[0089] In one embodiment, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the cedaridine is formulated for immediate release. In some embodiments, a portion of the cedaridine is formulated for immediate release, and the remainder of the cedaridine is formulated for modified release. For example, about 5%, 10%, 15%, 20%, 25%, 30%, 33.3%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the cedaridine (by weight) may be formulated for immediate release. In some embodiments, about 1 / 3 or 2 / 3 of the cedaridine (by weight) may be formulated for immediate release. In some embodiments, the cedaruridine is formulated for immediate release, and no cedaruridine is formulated for modified release. In some embodiments, substantially all cedaruridine is formulated for immediate release. In some such embodiments, the cedaruridine formulated for immediate release is uncoated. In some embodiments, the uncoated cedaruridine is a powder. In some embodiments, the uncoated cedaruridine is a blend (e.g., a powder blend). In some embodiments, the uncoated cedaruridine is in the form of granules. In some embodiments, the uncoated cedaruridine is in the form of pellets. In some embodiments, the uncoated cedaruridine is in the form of mini-tablets. In some embodiments of the pharmaceutical dosage form, the portion of the cedaruridine formulated for modified release is formulated for enteric release. In some embodiments of the pharmaceutical dosage form, the portion of the cedaruridine formulated for immediate release is provided as uncoated mini-tablets or pellets. Such uncoated mini-tablets or pellets form a core optionally coated with a release-modifying coating. Fixed-dose combination (immediate-release cedaruridine + modified-release azacitidine)

[0090] In some embodiments, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release and at least a portion of the cedaruridine is formulated for immediate release. In some embodiments, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release and all or substantially all of the cedaruridine is formulated for immediate release. In some embodiments, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein all or substantially all of the azacitidine is formulated for modified release and at least a portion of the cedaruridine is formulated for immediate release.

[0091] In some embodiments, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the azacitidine is formulated for modified release and the cedaridine is formulated for immediate release. The azacitidine formulated for modified release may be coated. In some embodiments, the coated azacitidine is in the form of pellets or mini-tablets. In some such embodiments, the cedaridine formulated for immediate release is uncoated. In some embodiments, the uncoated cedaridine is a powder. In some embodiments, the uncoated cedaridine is a blend (e.g., a powder blend). In some embodiments, the uncoated cedaridine is in the form of granules. In some embodiments, the uncoated cedaridine is in the form of pellets. In some embodiments, the uncoated cedaridine is in the form of mini-tablets. Each of the cedaridine and azacitidine can be formulated according to the following description. For example, the fixed dose combination, pharmaceutical dosage form or composition comprises cedaruridine in the form of an uncoated mini-tablet or pellet as described herein, and azacitidine in the form of a mini-tablet or pellet coated for modified release as described herein. The fixed dose combination can be provided in the form of a capsule. Sidacrudine preparations

[0092] The cedaruridine in the fixed dose combination, pharmaceutical dosage form or composition can be formulated so as to achieve the effect of enhancing the bioavailability of azacitidine. The cedaruridine in the fixed dose combination, pharmaceutical dosage form or composition can be in the form of a mini tablet, tablet, powder, blend, granule or pellet, and can further include lactose monohydrate, a filler, a binder, a disintegrant, a glidant and / or a lubricant. In some embodiments, the pharmaceutical dosage form of cedaruridine (i.e., cedaruridine minitablet, tablet, powder, blend, granule, or pellet) comprises about 10% to 90% w / w, about 10% to 80% w / w, about 10% to 60% w / w, or about 10% to 40% w / w cedaruridine, about 50% to 90% w / w cedaruridine, about 60% to 90% w / w cedaruridine, about 50% to 85% w / w cedaruridine, about 60% to 85% w / w cedaruridine, about 70% to 90% w / w cedaruridine, about 70% to 85% w / w cedaruridine, about 75% to 85% w / w cedaruridine, about 75% to 80% w / w cedaruridine, or about 75% to 80% w / w cedaruridine. % w / w of cedaridine, about 80% to 85% w / w of cedaridine, about 80% to 90% w / w of cedaridine, or about 70% to 80% w / w of cedaridine, about 15% to 40% w / w of cedaridine, about 25% to 40% w / w of cedaridine, about 20% to 40% w / w of cedaridine, about 30% to 40% w / w of cedaridine, about 15% to 35% w / w of cedaridine, about 15% to 30% w / w of cedaridine, or about 20% to 30% w / w of cedaridine, wherein the weight percentages are relative to the total weight of the uncoated cedaridine minitablet, tablet, powder, blend, granules or pellets.

[0093] In some embodiments, the cedaruridine is in the form of one or more tablets, mini-tablets or pellets. For example, the fixed-dose combination, pharmaceutical dosage form or composition may comprise azacitidine or a pharmaceutically acceptable salt thereof, and cedaruridine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is in the form of one or more tablets, mini-tablets or pellets, and the cedaruridine tablets, mini-tablets or pellets may comprise about 10% to 40% w / w cedaruridine, about 10% to 30% w / w, about 15% to 40% w / w, about 15% to 30% w / w, or about 15% to 25% w / w cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine tablets, mini-tablets or pellets. In some embodiments, the cedaruridine tablets, mini-tablets or pellets further comprise about 40% to 80% w / w lactose monohydrate, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine tablets, mini-tablets or pellets. In some embodiments, the cedaruridine pellets or mini-tablets comprise about 10% to 30% w / w cedaruridine, 40% to 80% w / w lactose monohydrate, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine tablets, mini-tablets or pellets. In some embodiments, the cedaruridine tablets, mini-tablets or pellets contain about 20% w / w cedaruridine, about 71.5% w / w lactose monohydrate, about 2% w / w hydroxypropyl methylcellulose (HPMC), about 5% w / w croscarmellose sodium, about 1.0% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine tablets, mini-tablets or pellets.

[0094] In some embodiments, the cedaruridine is in the form of a powder, blend or granules. For example, the fixed dose combination, pharmaceutical dosage form or composition may comprise azacitidine or a pharmaceutically acceptable salt thereof, and cedaruridine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is in the form of a powder or granules, and the cedaruridine powder or granules may comprise about 70% to 90% w / w cedaruridine, about 70% to 85% w / w cedaruridine, about 75% to 90% w / w cedaruridine, or about 75% to 85% w / w cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine powder or granules. The cedaruridine powder or granules may further comprise about 10% to 20% w / w lactose monohydrate, about 1% to 10.5% w / w cross-linked carboxymethylcellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine powder or granules. In some embodiments, the cedaruridine powder or granules comprises about 80% w / w cedaruridine, 13.5% w / w lactose monohydrate, about 5% w / w cross-linked carboxymethylcellulose sodium, about 1.0% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine powder or granules. Azacitidine preparations

[0095] Azacitidine in a fixed dose combination, pharmaceutical dosage form, or composition can be formulated such that the bioavailability of azacitidine is enhanced. In some embodiments of the fixed dose combination, pharmaceutical dosage form, or pharmaceutical composition, the azacitidine is provided as a mini-tablet or pellet. The uncoated azacitidine mini-tablet or pellet forms a core that is optionally coated with a release modifying coating. In some embodiments of the pharmaceutical dosage form, the portion of azacitidine formulated for modified release is provided as an enteric coated mini-tablet or pellet. In some embodiments, the enteric coating or the release modifying coating is pH sensitive.

[0096] The azacitidine mini-tablets or pellets include azacitidine and one or more pharmaceutically acceptable excipients, such as lactose monohydrate, a filler, a binder, a disintegrant, a glidant and / or a lubricant. The azacitidine minitablet or azacitidine pellet may contain about 10% to 70% w / w, about 10% to 60% w / w, about 10% to 50% w / w, about 10% to 40% w / w, about 15% to 40% w / w, about 20% to 40% w / w, about 25% to 40% w / w, about 30% to 40% w / w, about 20% to 60% w / w, about 25% to 50% w / w, about 25% to 45% w / w, about 30% to 45% w / w, about 20% to 60% w / w, about 20% to 50% w / w, about 30% to 50% w / w, or about 35% to 45% w / w of azacitidine, wherein the weight percentage is relative to the total weight of the uncoated minitablet or pellet. In some embodiments, the azacitidine mini-tablet or pellet comprises about 40% w / w azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet.

[0097] In some embodiments, the pharmaceutical dosage form comprises about 10% to 60% w / w lactose monohydrate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 10% to 50% w / w, about 10% to 40% w / w, about 10% to 30% w / w, or about 10% to 20% w / w lactose monohydrate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 10% to 60% w / w microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 10% to 50% w / w, about 20% to 40% w / w, or about 20% to 30% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.5 to 10% w / w of hydroxypropyl methylcellulose (HPMC), wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.5 to 8% w / w, about 0.5 to 6% w / w, about 0.5 to 4% w / w, or about 1 to 4% w / w of hydroxypropyl methylcellulose (HPMC), wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 1% to 10% w / w of croscarmellose sodium, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 1% to 8% w / w, about 2% to 8% w / w, or about 3% to 6% w / w of croscarmellose sodium, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.1% to 3% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.1% to 2% w / w, or about 0.5% to 2% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.1% to 3% w / w magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the pharmaceutical dosage form comprises about 0.1% to 2% w / w, or about 0.1% to 1% magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet.

[0098] In some embodiments, the azacitidine mini-tablets or pellets contain about 20% to 50% w / w azacitidine mini-tablets or pellets, about 10% to 60% w / w lactose monohydrate, about 2% to 50% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 4% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets. In some embodiments, the azacitidine mini-tablets or pellets contain about 40% w / w azacitidine, about 19.7% w / w lactose monohydrate, about 30% w / w microcrystalline cellulose, about 5% w / w croscarmellose sodium, about 2% w / w hydroxypropyl methylcellulose (HPMC), about 2.1% w / w silicon dioxide, and about 1.2% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets.

[0099] In some embodiments of the fixed-dose combination, pharmaceutical dosage form or composition, the azacitidine uncoated mini-tablet or pellet comprises one or more layers. For example, the azacitidine uncoated mini-tablet or pellet comprises one or more layers that may include an inner granule layer and an outer granule layer.

[0100] In some embodiments, the inner layer of the granule comprises about 70% to 92% w / w of azacitidine mini-tablets or pellets, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablets or pellets. In some embodiments, the inner layer of the granule comprises about 70% to 95% w / w, about 75% to 95% w / w, about 80% to 95% w / w, about 85% to 95% w / w, or about 90% to 92% of azacitidine mini-tablets or pellets, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablets or pellets. In some embodiments, the inner layer of the granule comprises about 90.5% w / w of azacitidine mini-tablets or pellets, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablets or pellets.

[0101] In some embodiments, in each uncoated mini-tablet or pellet, the inner layer of the granule comprises about 20% to 50% w / w of azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 20% to 60% w / w, about 25% to 50% w / w, about 25% to 45% w / w, about 30% to 45% w / w, or about 35% to 45% w / w of azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 10% to 60% w / w of lactose monohydrate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 10% to 40% w / w, about 10% to 30% w / w, or about 15% to 25% w / w of lactose monohydrate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 2% to 50% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 2% to 40% w / w, about 5% to 40% w / w, about 10% to 40% w / w, about 15% to 30% w / w, or about 20% to 30% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 1% to 10% w / w of cross-linked sodium carboxymethylcellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 1% to 10% w / w, about 1% to 8% w / w, about 1% to 6% w / w, or about 1% to 4% w / w of cross-linked sodium carboxymethylcellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 0.5% to 10% w / w of hydroxypropyl methylcellulose (HPMC), wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 0.5% to 8% w / w, about 0.5% to 6% w / w, about 0.5% to 4% w / w, or about 1% to 4% w / w of hydroxypropyl methylcellulose (HPMC), wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 0.1% to 3% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet.In some embodiments, the inner layer of the granule comprises about 0.1% to 2% w / w, or about 0.1% to 1% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 0.1% to 3% w / w of magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the inner layer of the granule comprises about 0.1% to 2% w / w, or about 0.1% to 1% w / w of magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet.

[0102] In some embodiments, the inner layer of the granule comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 50% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets. In some embodiments, the inner layer of the granule comprises about 40% w / w azacitidine, about 19.7% w / w lactose monohydrate, about 25% w / w microcrystalline cellulose, about 2.5% w / w cross-linked carboxymethyl cellulose sodium, about 2% w / w HPMC, about 0.5% w / w silicon dioxide, and about 0.8% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets.

[0103] In some embodiments, the outer layer of the granule comprises about 1% to 60% w / w microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 1% to 50% w / w, about 1% to 40% w / w, about 1% to 30%, about 1% to 20% w / w, or about 1% to 10% w / w microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 1% to 8% w / w, about 1% to 6% w / w, about 1% to 4% w / w, or about 2% to 4% w / w of cross-linked carboxymethylcellulose sodium, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 0.1% to 3% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 0.1% to 2% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 0.1% to 3% w / w of magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 0.1% to 2% w / w, or about 0.1% to 1% w / w magnesium stearate, wherein the weight percentage is relative to the total weight of the uncoated azacitidine minitablet or pellet.

[0104] In some embodiments, the outer layer of the granule comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some embodiments, the outer layer of the granule comprises about 5% w / w microcrystalline cellulose, about 2.5% w / w cross-linked carboxymethyl cellulose sodium, about 1.6% w / w silicon dioxide, and about 0.4% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet or pellet.

[0105] In some embodiments of the fixed-dose combination, pharmaceutical dosage form or composition, the azacitidine uncoated mini-tablet or pellet comprises an outer granule layer and an inner granule layer, wherein the inner granule layer comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 50% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose. (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, and wherein the outer layer of the granule comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets. In some embodiments, the inner layer of the granule comprises about 40% w / w azacitidine, about 19.7% w / w lactose monohydrate, about 25% w / w microcrystalline cellulose, about 2.5% w / w cross-linked sodium carboxymethyl cellulose, about 2% w / w HPMC, about 0.5% w / w silicon dioxide, and about 0.8% w / w magnesium stearate, and the outer layer of the granule comprises about 5% w / w microcrystalline cellulose, about 2.5% w / w cross-linked sodium carboxymethyl cellulose, about 1.6% w / w silicon dioxide, and about 0.4% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets.

[0106] In some embodiments of the fixed-dose combination, pharmaceutical dosage form or composition, the uncoated azacitidine mini-tablet or pellet comprises an outer granule layer and an inner granule layer, wherein the inner granule layer comprises about 20% to 50% w / w azacitidine, about 10% to 30% w / w lactose monohydrate, about 2% to 50% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, about 0.5% to 5% w / w binder (e.g., Kollidon VA64), and about 0.1% to 3% w / w magnesium stearate, and wherein the outer layer of the granules comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets or pellets. The outer layer of the granules comprises about 2% to 10% w / w microcrystalline cellulose, about 1% to 5% w / w cross-linked carboxymethyl cellulose sodium, about 0.1% to 1% w / w magnesium stearate, and about 1% to 5% of a binder (e.g., Kollidon VA64).

[0107] In some embodiments, the azacitidine mini-tablet or pellet is not separated into two layers and comprises about 2% to 10% w / w azacitidine, about 50% to 90% w / w lactose monohydrate, about 2% to 10% w / w croscarmellose sodium, about 1 to 5% w / w HPMC, about 0.1% to 3% colloidal silicon dioxide, and about 0.1% to 3% magnesium stearate. Coating

[0108] In some embodiments of the fixed-dose combination, pharmaceutical dosage form, or composition, the azacitidine formulated for modified release comprises an azacitidine minitablet or pellet as described herein, which is coated with one or more layers to achieve enteric release. In some embodiments of the fixed-dose combination, pharmaceutical dosage form, or composition, the azacitidine formulated for modified release comprises an azacitidine uncoated minitablet or pellet as described herein coated with one or more seal coating layers. In some embodiments, the minitablet or pellet coated with the seal coating is further coated with a second seal coating or an intermediate coating. In some embodiments, the seal-coated and second seal-coated minitablets or pellets are further coated with an enteric coating, a modified release coating, or a delayed release coating, providing 3 layers of coating. By way of example only, Examples 4 and 5 illustrate this embodiment. In some embodiments of the fixed-dose combination, the minitablet or pellet may be coated with a seal coating, and an enteric coating or a modified release coating, providing 2 layers of coating.

[0109] In some embodiments, the seal coat or the second seal coat comprises an ingredient that protects the tablet core, such as hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), magnesium oxide, or other ingredients suitable for seal coating of drugs.

[0110] The enteric coating or modified release coating comprises ingredients that protect the core tablet or pellet from the acidity of the stomach and allow release in the small intestine. In some embodiments, the delayed release coating comprises ethylcellulose, or an ethylcellulose-based polymer. For example, the delayed release coating comprises E-7-19040. In some embodiments, the delayed-release coating is insensitive to pH changes in the intestine. In some such embodiments, the azacitidine is released outside the stomach.

[0111] In some embodiments of the fixed dose combination, pharmaceutical dosage form or composition, the enteric or delayed release coating comprises a methacrylate-based polymer. In some embodiments, the enteric or delayed release coating may comprise L30D 55, FS 30D, FL 30D-55 or L100. In some embodiments, the enteric or delayed release coating may comprise methyl methacrylate-methacrylic acid copolymer, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate succinate, polyvinyl acetate phthalate or a copolymer thereof. The enteric or delayed release coating may further comprise triethyl citrate and / or talc. In some embodiments, the enteric delayed release coating is sensitive to pH changes in the intestine. In some such embodiments, depending on the polymer present in the coating, the enteric or delayed release coating is selected to provide release in the duodenum, jejunum, ileum or colon. In some such embodiments, the azacitidine is released outside the stomach. By way of example only, Example 6 illustrates such an embodiment.

[0112] The coating for azacitidine tablets or pellets can be applied in an amount suitable to provide the desired release profile. In some embodiments, the total coating of azacitidine tablets or pellets may have a weight gain of about 5 to 25%, about 10 to 25%, about 15 to 25%, about 20 to 25%, about 5 to 20%, about 10 to 20%, about 15 to 20%, about 5 to 15%, about 10 to 15%, or about 5 to 10% compared to uncoated azacitidine tablets or pellets. In some embodiments, the enteric or delayed release coating of azacitidine tablets or pellets may have a weight gain of about 3 to 15%, about 3 to 12%, about 3 to 10%, about 4 to 10%, or about 4 to 7% compared to uncoated azacitidine tablets or pellets. Implementation

[0113] In some or any of the foregoing embodiments, provided herein is a fixed dose combination, pharmaceutical dosage form or pharmaceutical composition comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release and is provided as a powder, granules, pellets or mini-tablets; and all of the azacitidine is formulated for modified release and is provided as an enteric coated mini-tablet or pellet. The fixed dose combination can be provided in a capsule.

[0114] In some such embodiments, the azacitidine mini-tablet or pellet comprises an inner granule layer and an outer granule layer. The inner granule layer comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 50% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate. The outer granule layer comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some such embodiments, the inner layer of the granule comprises about 40% w / w azacitidine, about 19.7% w / w lactose monohydrate, about 25% w / w microcrystalline cellulose, about 2.5% w / w croscarmellose sodium, about 2% w / w HPMC, about 0.5% w / w silicon dioxide, and about 0.8% w / w magnesium stearate, and the outer layer of the granule comprises about 5% w / w microcrystalline cellulose, about 2.5% w / w croscarmellose sodium, about 1.6% w / w silicon dioxide, and about 0.4% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet or pellet. In some such embodiments, the azacitidine mini-tablet or pellet is coated with a seal coat and an enteric or modified release coating. The enteric or modified release coating comprises a polymethacrylate-based polymer and is sensitive to the pH in the intestine. The azacitidine is released substantially outside the stomach.

[0115] In some such embodiments, the cedaruridine is provided as pellets or mini-tablets and the cedaruridine pellets or mini-tablets comprise about 10% to 30% w / w cedaruridine, 40% to 80% w / w lactose monohydrate, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine tablets, mini-tablets or pellets. In some such embodiments, the cedaruridine tablet, mini-tablet or pellet comprises about 20% w / w cedaruridine, about 71.5% w / w lactose monohydrate, about 2% w / w hydroxypropyl methylcellulose (HPMC), about 5% w / w croscarmellose sodium, about 1.0% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine tablet, mini-tablet or pellet.

[0116] In other such embodiments, the cedaruridine is in powder form, and the cedaruridine powder may comprise about 70% to 90% w / w cedaruridine, about 10% to 20% w / w lactose monohydrate, about 1% to 10.5% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine powder or granules. In some embodiments, the cedaruridine powder or granules comprise about 80% w / w cedaruridine, 13.5% w / w lactose monohydrate, about 5% w / w croscarmellose sodium, about 1.0% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine powder or granules.

[0117] In some or any of the foregoing embodiments, provided herein is a pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release; at least a portion of the azacitidine is formulated for immediate release and is provided as an uncoated mini-tablet or pellet, and the remainder of the azacitidine is formulated for modified release and is provided as an enteric coated mini-tablet or pellet. In some such embodiments, the azacitidine mini-tablet or pellet is uniform (i.e., does not comprise an inner granular layer and an outer granular layer). In some other such embodiments, the azacitidine mini-tablet or pellet comprises an inner granular layer and an outer granular layer.

[0118] In some or any of the foregoing embodiments, provided herein is a pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release; and all of the azacitidine is formulated for modified release and provided as a delayed release mini-tablet or pellet. In some such embodiments, the azacitidine pellet comprises an inner granule layer and an outer granule layer. In some such embodiments, the azacitidine pellet is uniform (i.e., does not comprise an inner granule layer and an outer granule layer). Fixed-dose combination – tablets

[0119] In some embodiments, provided herein is a fixed dose combination (FDC) pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine and azacitidine are formulated for immediate release. In some such embodiments, the dosage form is a tablet. In some embodiments, the tablet is an uncoated tablet, such as the FDC tablet of Example 12.

[0120] In some embodiments, the FDC tablet comprises an inner granular layer and an outer granular layer. In some embodiments, the inner granular layer accounts for about 50% to 90% w / w of the FDC tablet, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the outer granular layer accounts for about 10% to 50% w / w of the FDC tablet, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granular layer accounts for about 80% w / w of the FDC tablet, and the outer granular layer accounts for about 20% w / w of the FDC tablet, wherein the weight percentage is relative to the total weight of the FDC tablet.

[0121] In some embodiments, the inner granule layer of the FDC tablet comprises about 1% to 10% w / w of cedaridine, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granule layer of the FDC tablet comprises about 1 to 10% w / w of azacitidine, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granule layer of the FDC tablet comprises about 10% to 60% w / w of lactose monohydrate, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granule layer of the FDC tablet comprises about 10% to 50% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granule layer of the FDC tablet comprises about 1% to 10% w / w of cross-linked carboxymethylcellulose sodium, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granular layer of the FDC tablet comprises about 1% to 10% w / w HPMC, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granular layer of the FDC tablet comprises about 0.1% to 5% w / w silicon dioxide, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granular layer of the FDC tablet comprises about 0.1% to 5% w / w magnesium stearate, wherein the weight percentage is relative to the total weight of the FDC tablet.

[0122] In some embodiments, the outer granular layer of the FDC tablet comprises about 5% to 30% w / w microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the outer granular layer of the FDC tablet comprises about 1% to 10% w / w cross-linked carboxymethyl cellulose sodium, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the outer granular layer of the FDC tablet comprises about 1% to 5% w / w silicon dioxide, wherein the weight percentage is relative to the total weight of the FDC tablet. In some embodiments, the inner granular layer of the FDC tablet comprises about 0.1% to 5% w / w magnesium stearate, wherein the weight percentage is relative to the total weight of the FDC tablet.

[0123] In some embodiments, provided herein is a fixed dose combination pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine and azacitidine are formulated for immediate release, and the dosage form is further coated with an enteric coating. In some such embodiments, the dosage form is a tablet. In some embodiments, the tablet is a coated tablet, such as the coated FDC tablet of Example 1. In some embodiments, the tablet is coated with a seal coat and then coated with an enteric coating. Fixed-dose combinations - enteric-coated capsules

[0124] In some embodiments, provided herein is a fixed-dose combination pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine and azacitidine are formulated for immediate release, and the dosage form is a capsule. In some embodiments, the capsule may be coated to provide an enteric-coated capsule.

[0125] In one embodiment, provided herein is a capsule comprising azacitidine, wherein the capsule comprises an enteric-coated capsule shell. In some embodiments, the capsule further comprises cedaruridine. In some such embodiments, the azacitidine and / or cedaruridine may be filled in a capsule with additional excipients. In some embodiments, the azacitidine and / or cedaruridine filled in the capsule may be in the form of a powder, blend, granules, pellets, mini-tablets, or a combination thereof.

[0126] In some embodiments, the capsule shell is an enteric-coated capsule shell comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and / or hydroxypropylmethylcellulose (HPMC). Enteric-coated capsules. Enteric-coated capsules are prepared with pharmaceutical-grade enteric-coated cellulose derivatives (e.g., HPMCAS, HPMC). In some embodiments, the capsules further comprise a gelling agent and water. In some embodiments, the capsules further comprise at least one alkaline compound or alkaline composition capable of neutralizing the succinic acid groups on HPMCAS, including but not limited to alkaline hydroxide compounds such as potassium hydroxide (KOH), sodium hydroxide (NaOH), calcium hydroxide (Ca(OH)2) or other alkaline compounds or compositions, such as ammonium hydroxide, cationic polymers (such as In some embodiments, the enteric-coated capsule shell allows the azacitidine and / or cedaruridine to be released substantially outside the stomach. In some embodiments, the enteric-coated capsule shell allows enteric release of azacitidine. In some embodiments, the enteric release is a delayed release that is sensitive to pH changes in the intestine.

[0127] In some embodiments, the enteric-coated capsule shell comprises a solid filled in the enteric-coated capsule shell. In some embodiments, the solid filled in the enteric-coated capsule shell comprises azacitidine and another excipient. In some embodiments, the solid filled in the enteric-coated capsule shell comprises azacitidine and another excipient, and further comprises cedaruridine and another excipient.

[0128] In some embodiments, the capsule comprises a buffer salt therein. In some embodiments, the buffer salt is selected from sodium phosphate (including sodium dihydrogen phosphate, disodium hydrogen phosphate), potassium phosphate, 2-amino-2-hydroxymethyl-propane-1,3-diol (tris), sodium hydroxide, sodium citrate, sodium acetate, potassium acetate, citric acid and sodium or potassium citrate, amino acid salts, malic acid and sodium or potassium malate, tartaric acid and potassium or sodium tartrate, glutamic acid and sodium or potassium glutamate, and sodium carbonate.

[0129] In some embodiments, the capsule further comprises about 10% to 50% w / w, about 10% to 40% w / w, about 10% to 30% w / w, or about 10% to 20% w / w of lactose monohydrate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 26.2% w / w of lactose monohydrate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 10% to 50% w / w, about 10% to 40% w / w, about 10% to 30% w / w, or about 20% to 30% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 25.7% w / w of microcrystalline cellulose, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 1% to 25% w / w, about 1% to 20% w / w, about 5% to 20% w / w, about 5% to 15% w / w, or about 5% to 10% w / w of cross-linked sodium carboxymethylcellulose, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 8% w / w of cross-linked sodium carboxymethylcellulose, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 1% to 10% w / w, about 1% to 8% w / w, about 1% to 6% w / w, or about 1% to 4% w / w of HPMC, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 2% w / w of HPMC, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 1% to 10% w / w, about 1% to 8% w / w, about 1% to 6% w / w, or about 1% to 4% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 2.1% w / w of silicon dioxide, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 0.1 to 10% w / w, about 0.1 to 8% w / w, about 0.1 to 5% w / w, about 0.1 to 2% w / w, or about 0.1 to 1% w / w of magnesium stearate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 1% w / w of magnesium stearate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell.

[0130] In some embodiments, the capsule further comprises about 10% to 50% w / w lactose monohydrate, about 10% to 50% w / w microcrystalline cellulose, about 1% to 20% w / w croscarmellose sodium, about 1% to 10% w / w HPMC, about 1% to 10% w / w silicon dioxide, and about 0.1% to 5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 26.2% w / w lactose monohydrate, about 25.7% w / w microcrystalline cellulose, about 8% w / w croscarmellose sodium, about 2% w / w HPMC, about 2.1% w / w silicon dioxide, and about 1% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the solids filled in the capsule shell.

[0131] In some embodiments, the capsule comprises about 5% to 40% w / w azacitidine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 5% to 30% w / w, about 5% to 25% w / w, about 5% to 20% w / w, or about 5% to 15% w / w azacitidine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 10% w / w azacitidine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell.

[0132] In some embodiments, the capsule comprises about 5% to 40% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 5% to 30% w / w, about 5% to 25% w / w, about 5% to 20% w / w, or about 5% to 15% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 10% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell.

[0133] In some embodiments, the capsule further comprises about 5% to 25% w / w sodium phosphate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 1% to 30% w / w, about 1% to 25% w / w, about 1% to 20% w / w, about 1% to 10% w / w, about 5% to 20% w / w, or about 5% to 10% w / w sodium phosphate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule further comprises about 15% w / w sodium phosphate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In any of these embodiments, the sodium phosphate is anhydrous disodium hydrogen phosphate.

[0134] In some embodiments, the capsule comprises about 2% to 20% w / w of sidaridine, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule comprises about 2% to 20% sidaridine, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule comprises about 1% to 40% w / w lactose monohydrate, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule comprises about 1% to 40% w / w microcrystalline cellulose (e.g., Avicel PH102, Avicel PH200), wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule comprises about 5% to 25% w / w sodium phosphate, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some such embodiments, the sodium phosphate is disodium hydrogen phosphate. In some such embodiments, the sodium phosphate is anhydrous. In some other embodiments, the capsule does not contain any sodium phosphate. In some embodiments, the capsule contains about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule contains about 0% to 15% HPMC (also referred to herein as hydroxypropyl methylcellulose). In some embodiments, the capsule does not contain any HPMC. In some embodiments, the capsule contains about 1% to 4% colloidal silicon dioxide, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule contains about 0.25% to 4% magnesium stearate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell.

[0135] In some embodiments, the capsule comprises about 8 to 10% w / w of sidaridine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 8% to 10% azacitidine, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 25% to 35% w / w lactose monohydrate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 22% to 26% w / w microcrystalline cellulose (e.g., Avicel PH102, Avicel PH200), wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some embodiments, the capsule comprises about 15% w / w sodium phosphate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some such embodiments, the sodium phosphate is disodium hydrogen phosphate, wherein the weight percentage is relative to the total weight of the solids filled in the capsule shell. In some such embodiments, the sodium phosphate is anhydrous. In some other embodiments, the capsule does not contain any sodium phosphate. In some embodiments, the capsule contains about 8% w / w of cross-linked carboxymethylcellulose sodium, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule contains about 2% HPMC (also referred to herein as hydroxypropyl methylcellulose), wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule does not contain any HPMC, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule contains about 2% to 2.5% colloidal silicon dioxide, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. In some embodiments, the capsule contains about 1% to 1.5% magnesium stearate, wherein the weight percentage is relative to the total weight of the solid filled in the capsule shell. dose

[0136] In some embodiments, the pharmaceutical dosage form comprises about 5 to about 200 mg, about 10 to about 300 mg, about 20 to about 300 mg, about 20 to about 200 mg, about 20 to about 100 mg, about 5 to about 100 mg, about 5 to about 80 mg, about 20 to about 80 mg, about 5 to about 60 mg, about 20 to about 60 mg, about 5 to about 50 mg, about 30 to about 50 mg, about 10 to about 30 mg, about 30 to about 300 mg. g, about 40 to about 300 mg, about 50 to about 300 mg, about 50 to about 250 mg, about 50 to about 200 mg, about 60 to about 150 mg, about 70 to about 150 mg, about 70 to about 140 mg, about 80 to about 130 mg, about 90 to about 120 mg, about 90 to about 110 mg, about 10 to about 100 mg, about 10 to about 70 mg, about 20 to about 50 mg of cedaruridine as an active pharmaceutical ingredient. In some embodiments, the pharmaceutical dosage form comprises about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mg of cedaruridine as an active pharmaceutical ingredient.

[0137] In some embodiments, the pharmaceutical dosage form comprises about 5 to about 100 mg, about 20 to about 120 mg, about 40 to about 120 mg, about 60 to about 120 mg, about 80 to about 120 mg, about 100 to about 120 mg, about 5 to about 80 mg, about 10 to about 80 mg, about 10 to about 70 mg, about 20 to about 70 mg, about 20 to about 65 mg, about 25 to about 65 mg, about 25 to about 60 mg, about 30 to about 55 mg, about 30 to about 50 mg, about 35 to about 50 mg, or about 35 to about 45 mg of azacitidine as an active pharmaceutical ingredient. In some embodiments, the pharmaceutical dosage form comprises about 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, or 120 mg of azacitidine as the active pharmaceutical ingredient.

[0138] Any suitable combination of the amounts of azacitidine and cedaruridine described herein may be included in a fixed dose combination dosage form. For example, the fixed dose combination may include about 5 to about 200 mg of cedaruridine and about 20 to about 160 mg of azacitidine. In some such embodiments, the fixed dose combination may include about 5 to about 100 mg of cedaruridine and about 20 to about 140 mg of azacitidine. In some such embodiments, the fixed dose combination may include about 5 to about 80 mg of cedaruridine and about 40 to about 140 mg of azacitidine. In some such embodiments, the fixed dose combination may include about 5 to about 60 mg of cedaruridine and about 60 to about 140 mg of azacitidine, about 5 to about 40 mg of cedaruridine and about 60 to about 120 mg of azacitidine, or about 10 to about 40 mg of cedaruridine and about 80 to about 120 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 80 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 84 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 88 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 92 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 96 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 100 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 104 mg of azacitidine. In some embodiments, the fixed dose combination may include about 20 mg of cedaruridine and about 108 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 20 mg of cedaruridine and about 112 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 20 mg of cedaruridine and about 120 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 100 mg of cedaruridine and about 40 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 20 mg of cedaruridine and about 40 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 40 mg of cedaruridine and about 100 mg of azacitidine. In some embodiments, the fixed dose combination may comprise about 40 mg of cedaruridine and about 80 mg of azacitidine, about 40 mg of cedaruridine and about 84 mg of azacitidine, about 40 mg of cedaruridine and about 88 mg of azacitidine, about 40 mg of cedaruridine and about 92 mg of azacitidine, or about 40 mg of cedaruridine and about 96 mg of azacitidine.

[0139] In some embodiments, the pharmaceutical dosage form or the fixed dose combination can be about 1:20 to about 10:1, about 1:10 to about 10:1, about 1:8 to about 1:1, about 1:8 to about 1:2, about 1:8 to about 1:4, about 1:6 to about 1:1, about 1:6 to about 1:2, about 1:6 to about 1:3, about 1:6 to about 1:4, about 1:6 to about 1:5, about 1:5 to about 5:1, A ratio of about 1:5 to about 1:1, about 1:5 to 1:2, about 1:5 to 1:3, about 1:5 to 1:4, about 1:4 to about 4:1, about 1:4 to about 1:1, about 1:3 to about 3:1, about 1:2 to about 2:1, about 1:1 to about 1:5, about 1:1 to about 1:4, about 1:1 to about 1:3, or about 1:1 to about 1:2 comprises cedaridine and azacitidine. In some embodiments, the fixed dose combination may comprise cedaruridine and azacitidine in a ratio of about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 3:4, about 3:5, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1.5:1, about 2:1, about 2.5:1, about 4:3, about 4:1, or about 5:3 by weight.

[0140] The specific dosage level of the composition of the present application for any particular subject will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, administration time, administration route, and excretion rate, drug combination, and the severity of the specific disease in the subject undergoing therapy. For example, the dosage can be expressed as milligrams of the compound described herein per kilogram of subject body weight (mg / kg). A dosage of about 0.1 to 150 mg / kg of sidaridine and / or azacitidine may be suitable. In some embodiments, about 0.1 and 100 mg / kg may be suitable. In other embodiments, a dosage between 0.5 and 60 mg / kg may be suitable. When adjusting the dosage between subjects of widely unequal body sizes, normalization according to the subject's body weight is particularly useful, such as when the drug is used in children and adult humans or when the effective dose is converted into a dose suitable for human subjects in non-human subjects (such as dogs).

[0141] The daily dose may also be described as the total amount of cedaruridine and / or azacitidine administered per dose or per day. The daily dose of cedaruridine and / or azacitidine may be between about 1 mg to 4,000 mg, between about 2,000 to 4,000 mg / day, between about 1 to 2,000 mg / day, between about 1 to 1,000 mg / day, between about 10 to 500 mg / day, between about 20 to 500 mg / day, between about 50 to 300 mg / day, between about 75 to 200 mg / day, or between about 15 to 150 mg / day.

[0142] When administered orally, the total daily dosage for human subjects may be between 1 mg and 1,000 mg, between about 1,000 and 2,000 mg / day, between about 10 and 500 mg / day, between about 50 and 300 mg / day, between about 75 and 200 mg / day, or between about 100 and 150 mg / day.

[0143] The compositions of the present application can be administered once, twice, three times or four times a day using any suitable mode described above. In addition, administration of the compound or treatment with the compound can last for several days; for example, typically, the treatment will last for at least 7 days, 14 days or 28 days for a treatment cycle. Treatment cycles are well known in cancer chemotherapy, and frequently the rest time of about 1 to 28 days, typically about 7 days or about 14 days, is alternated between cycles. In other embodiments, the treatment cycle can also be continuous. Treatment methods and uses

[0144] "Treatment" or "treating" is a method for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting a disease or condition (e.g., reducing one or more symptoms due to the disease or condition, and / or eliminating the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread of the disease or condition (e.g., metastasis); and / or c) relieving the disease, i.e., causing regression of clinical symptoms (e.g., improving the disease state, providing partial or complete regression of the disease or condition, enhancing the effect of another drug, delaying the progression of the disease, improving the quality of life, and / or prolonging survival).

[0145] "Prevention" or "preventing" means any treatment of a disease or condition that does not develop the clinical symptoms of the disease or condition. In some embodiments, the compound can be administered to a subject (including humans) who is at risk for or has a family history of the disease or condition.

[0146] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation, or experiment. The methods described herein can be used for human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

[0147] The term "therapeutically effective amount" or "effective amount" of a compound described herein, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug or deuterated analog thereof, means an amount sufficient to achieve treatment to provide a therapeutic benefit (such as improving symptoms or slowing disease progression) when administered to a subject. For example, a therapeutically effective amount may be an amount sufficient to reduce the symptoms of cancer. The therapeutically effective amount may vary depending on the subject, and the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, and the mode of administration, which can be readily determined by one of ordinary skill in the art.

[0148] Provided herein is a method for treating a patient's cancer, comprising administering any dosage form described herein to a subject in need thereof. In some embodiments, the cancer is selected from hematological cancer and solid cancer. In other embodiments, the hematological cancer is selected from myelodysplastic syndrome (MDS) and leukemia. In other embodiments, the solid cancer is selected from pancreatic cancer, ovarian cancer, prostate cancer, peritoneal cancer, non-small cell lung cancer and breast cancer. In other embodiments, the leukemia is acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). In some embodiments, the AML is relapsed or refractory AML. In some embodiments, the AML may be before or after hematopoietic cell transplantation. In some embodiments, the cancer is mucosal melanoma. In some embodiments, the leukemia is relapsed or refractory acute biphenotypic leukemia. In some embodiments, the AML patient may have achieved the first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after enhanced induction chemotherapy and cannot complete enhanced curative therapy.

[0149] In some embodiments, the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML or CMMoL), previously treated or untreated primary or secondary chronic myeloid leukemia (CML), and previously treated or untreated primary or secondary juvenile myelomonocytic leukemia (JMML). In some embodiments, the MDS may be intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

[0150] In some embodiments, the cancer is associated with refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts-transition (RAEB-T).

[0151] In some embodiments, the cancer is selected from malignant peripheral nerve sheath tumor (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC), and lung cancer.

[0152] In some embodiments, the patient has moderate or severe liver damage. In some embodiments, the patient has normal liver function.

[0153] In some embodiments, the patient has moderate or severe renal impairment. In some embodiments, the patient has normal renal function.

[0154] In some embodiments, the pharmaceutical dosage forms described herein can be administered orally. In some embodiments, the pharmaceutical dosage forms described herein can be administered once, twice, or three times a day. In some embodiments, the pharmaceutical dosage forms described herein can be administered once a day or once in 2, 3, 4, 5, 6, or 7 days. In some embodiments, the pharmaceutical dosage forms described herein can be administered in cycles. For example, the pharmaceutical dosage forms described herein can be administered for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days in each cycle.

[0155] Also provided is a pharmaceutical dosage form as described herein for use in treating cancer. Combination therapy

[0156] In one embodiment, the compounds, pharmaceutical compositions and / or dosage forms disclosed herein can be used in combination with one or more additional therapeutic agents being used and / or developed to treat cancer, T-cell lymphoma (such as bone marrow / stem cell transplantation and / or CAR T cell therapy). In some embodiments, the pharmaceutical compositions or dosage forms described herein may include one or more anticancer agents in addition to azacitidine and cedaruridine.

[0157] The different agents may be administered sequentially or simultaneously (contained in separate compositions or in the same composition). Useful classes of agents for combination therapy include, but are not limited to, kinase inhibitors, CD4+ inhibitors, anti-PD-1 monoclonal antibodies.

[0158] In some embodiments, the one or more additional therapeutic agents may be tolinapant or venetoclax. In some embodiments, the dosage form may include tolinapant and / or venetoclax in addition to azacitidine and cedaruridine.

[0159] In some embodiments, the pharmaceutical composition comprising azacitidine and cedaruridine can be administered in combination with other therapeutic agents. In some embodiments, the other therapeutic agent can be selected from the group consisting of: ADI-PEG 20, AMG-176, APG-115, APR-246, avelumab, bendamustine, bisantrene, brentuximab vedotin), capecitabine, CB-839, cisplatin, CS-01, cusatuzumab, cyclophosphamide, cytarabine, dasatinib, daunorubicin, DCLL9718S, decitabine, deferasirox, dexamethasone, durvalumab, eltrombopag, enasidenib, entinostat, entrectinib, enzalutamide, epacadostat, erythropoetin, etoposide, evorpacept, filgrastim, fludarabine phosphate), flumatinib, gemcitabine, gemtuzumabozogamicin), gilteritinib, GM-CSF, GSK2879552, HMPL-523, homoharringtonine, IBI188, ibrutinib, idarubicin, itacitinib, ivosidenib, jaktinib, KPT-8602, LDE255, lenalidomide, lirilumab, LP-1 08. magrolimab, MAX-40279, mitoxantrone, mitoxantrone liposome, mocetinostat, moxifloxacin, nivolumab, olutasidenib, omacetaxine, oxaliplatin, paclitaxel, pembrolizumab, pevonedistat t), pinometostat, pracinostat, quizartinib, Revlimid, rigosertib, rituximab, romidepsin, RP7214, S64315, S65487, sabatolimab, seclidemstat, selumetinib, siremadlin, sirol imus), SL-401, SNDX-5613, sorafenib, talazoparib, tamibarotene, torinapan, trastuzumab, tucidinostat, tyrosine kinase inhibitors, Uproleselan, Velcade, venetoclax, vincristine, visilizumab, vorinostat, and vosaroxin. In the treatment of any condition described herein, the pharmaceutical compositions or dosage forms described herein can be administered in combination with non-chemotherapeutic treatments such as iron, all-trans retinoic acid, allogeneic stem cell transplantation, and / or platelet transfusions. Reagent test kit

[0160] Provided herein are kits comprising the disclosed dosage forms and suitable packaging. In one embodiment, the kit further comprises a label and / or instructions for using the dosage form in a therapeutic indication, including a disease or condition described herein. Dosage form and excipients

[0161] The oral dosage forms described herein are prepared in a manner well known in the pharmaceutical art. See, for example, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th edition (1985); and Modern Pharmaceutics, Marcel Dekker, Inc., 3rd edition (GS Banker and CT Rhodes, eds.).

[0162] Some embodiments described herein may be modified to include any additional suitable excipients. Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup and methylcellulose. The formulation may additionally include lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl hydroxybenzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents.

[0163] To prepare solid compositions such as tablets or capsules, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug or deuterated analog thereof. When referring to these preformulation compositions as homogeneous, the active ingredient is dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pellets and capsules.

[0164] The tablets or pellets of the compounds described herein can be formulated to provide a dosage form that imparts an extended effect advantage or protects against the acid conditions of the stomach. For example, the tablet or pellet may include an inner dose and an outer dose component, the latter being in the form of a shell or coating on the former. The two components can be separated by a seal coating layer, which is used to resist disintegration in the stomach and allow the inner component to enter the duodenum intact or delay release. A variety of materials can be used for such enteric layers or coatings, including many polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0165] In some embodiments, the pellets and / or tablets described herein further comprise a film coating, for example, for limiting photolytic degradation. Suitable film coatings are selected by routine screening of commercially available preparations. In one embodiment, the film coating may be a polyvinyl alcohol-based coating. In some embodiments, the pharmaceutical compositions as described herein are formulated into unit dosage forms or pharmaceutical dosage forms. The term "unit dosage form" or "pharmaceutical dosage form" refers to a physically discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect in combination with a suitable pharmaceutical excipient and provided, for example, in a capsule. The dosage form is generally administered in a pharmaceutically effective amount. In some embodiments, the dosage form is placed / stored in an aluminum strip package, a moisture-proof blister foil, or a bottle package. Implementation

[0166] Embodiment 1. A pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release.

[0167] Embodiment 2. The dosage form of embodiment 1, wherein at least a portion of the azacitidine is formulated for immediate release.

[0168] Embodiment 3. The dosage form of embodiment 1 or embodiment 2, wherein the cedaruridine is formulated for immediate release.

[0169] Embodiment 4. The dosage form of embodiment 3, wherein the cedaruridine is uncoated and is in the form of mini-tablets, powder, blend, granules or pellets.

[0170] Embodiment 5. The dosage form according to any of the preceding embodiments, comprising about 10% to 40% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine minitablet, powder, blend, granules or pellets.

[0171] Embodiment 6. The dosage form of embodiment 5, comprising about 20% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine minitablet, powder, blend, granules or pellets.

[0172] Embodiment 7. The dosage form of any of the preceding embodiments, further comprising about 40% to 80% w / w lactose monohydrate, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine minitablets, powder, blend, granules or pellets.

[0173] Embodiment 8. The dosage form of embodiment 7, further comprising about 71.5% w / w lactose monohydrate, about 2% w / w hydroxypropyl methylcellulose (HPMC), about 5% w / w croscarmellose sodium, about 1% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine minitablets, powder, blend, granules or pellets.

[0174] Embodiment 9. The dosage form according to any one of the preceding embodiments, wherein the cedaruridine is in the form of mini-tablets or pellets.

[0175] Embodiment 10. The dosage form according to any one of the preceding embodiments, wherein the portion of the azacitidine formulated for modified release is formulated for enteric release.

[0176] Embodiment 11. The dosage form according to any one of the preceding embodiments, wherein the portion of azacitidine formulated for immediate release is provided as an uncoated mini-tablet.

[0177] Embodiment 12. The dosage form of embodiment 1, wherein the portion of azacitidine formulated for modified release is provided as an enteric coated minitablet.

[0178] Embodiment 13. The dosage form according to any of the preceding embodiments, comprising about 20% to 60% w / w azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine minitablet.

[0179] Embodiment 14. The dosage form according to any one of the preceding embodiments, comprising about 40% w / w azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine minitablet.

[0180] Embodiment 15. The dosage form according to any one of the preceding embodiments, further comprising lactose monohydrate, a filler, a binder, a disintegrant, a glidant and a lubricant.

[0181] Embodiment 16. A dosage form as described in any of the preceding embodiments, further comprising about 10% to 60% w / w lactose monohydrate, about 10% to 60% w / w microcrystalline cellulose, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w cross-linked carboxymethylcellulose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablets.

[0182] Embodiment 17. A dosage form as described in any of the preceding embodiments, further comprising about 48.5% w / w lactose monohydrate, about 25% w / w microcrystalline cellulose, about 2% w / w hydroxypropyl methylcellulose (HPMC), about 5% w / w cross-linked carboxymethyl cellulose sodium, about 1% w / w silicon dioxide, and about 0.5% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine minitablets.

[0183] Embodiment 18. The dosage form of embodiment 11, wherein the azacitidine uncoated mini-tablet comprises an inner granule layer and an outer granule layer.

[0184] Embodiment 19. A dosage form according to embodiment 18, wherein the inner layer of the granule comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

[0185] Embodiment 20. A dosage form according to embodiment 18 or 19, wherein the outer layer of the granules comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

[0186] Embodiment 21. The dosage form of any one of the preceding embodiments, wherein the portion of azacitidine formulated for enteric release comprises an azacitidine uncoated minitablet coated with a seal coat.

[0187] Embodiment 22. The dosage form of embodiment 21, wherein the seal coat comprises hydroxypropyl methylcellulose (HPMC).

[0188] Embodiment 23. The dosage form of embodiment 21 or 22, wherein the mini-tablet coated with the seal coating is further coated with an enteric coating.

[0189] Embodiment 24. The dosage form of embodiment 23, wherein the enteric coating comprises ethylcellulose.

[0190] Embodiment 25. The dosage form of embodiment 23 or 24, wherein the enteric coating is insensitive to pH changes in the intestine.

[0191] Embodiment 26. The dosage form of embodiment 23, wherein the enteric coating comprises polymethacrylate or a copolymer thereof.

[0192] Embodiment 27. The dosage form of embodiment 23 or 26, wherein the enteric coating is sensitive to pH changes in the intestine.

[0193] Embodiment 28. The dosage form of any of the preceding embodiments, wherein about 0% to about 60% of the azacitidine is provided as an uncoated minitablet and about 100% to about 50% of the azacitidine is provided as a modified release coated minitablet.

[0194] Embodiment 29. The dosage form of any one of embodiments 1 to 27, wherein about 37% to about 60% of the azacitidine is provided as an uncoated minitablet and about 40% to about 63% of the azacitidine is provided as a modified release coated minitablet.

[0195] Embodiment 30. The dosage form of any one of embodiments 1, 3 to 28, wherein all of the azacitidine is formulated for modified release.

[0196] Embodiment 31. The dosage form of any one of embodiments 1, 3 to 28, wherein substantially all of the azacitidine is released extragastrically.

[0197] Embodiment 32. A pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release; at least a portion of the azacitidine is formulated for immediate release and provided as an uncoated minitablet, and the remainder of the azacitidine is formulated for modified release and provided as an enteric-coated minitablet.

[0198] Embodiment 33. A pharmaceutical dosage form comprising chiduridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the chiduridine is formulated for immediate release; and the azacitidine is formulated for modified release and is provided as an enteric-coated mini-tablet.

[0199] Embodiment 34. The dosage form of embodiment 32 or embodiment 33, wherein the azacitidine mini-tablet comprises an inner granule layer and an outer granule layer.

[0200] Embodiment 35. A pharmaceutical dosage form comprising chiduridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the chiduridine is formulated for immediate release; and the azacitidine is formulated for modified release and is provided as a delayed release mini-tablet.

[0201] Embodiment 36. The dosage form of embodiment 35, wherein the azacitidine mini-tablet comprises an inner granule layer and an outer granule layer.

[0202] Embodiment 37. The dosage form of any one of embodiments 32 to 36, wherein the cedaruridine is uncoated and is in the form of mini-tablets, powder, blend, granules or pellets.

[0203] Embodiment 38. The dosage form of embodiment 37, comprising about 20% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine minitablet, powder, blend, granules or pellets.

[0204] Embodiment 39. The dosage form of any one of embodiments 32 to 38, comprising about 40% w / w azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine minitablet.

[0205] Embodiment 40. The dosage form according to any one of the preceding embodiments, wherein the dosage form is a capsule comprising one or more cedaruridine mini-tablets and one or more azacitidine mini-tablets.

[0206] Embodiment 41. A fixed-dose combination pharmaceutical dosage form comprising chiduridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the chiduridine and azacitidine are formulated for immediate release.

[0207] Embodiment 42. The dosage form of embodiment 41, wherein the dosage form is a tablet.

[0208] Embodiment 43. A fixed-dose combination pharmaceutical dosage form comprising chiduridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein the chiduridine and azacitidine are formulated for immediate release, and the dosage form is further coated with an enteric coating.

[0209] Embodiment 44. The dosage form of embodiment 43, wherein the dosage form is a tablet.

[0210] Embodiment 45. A pharmaceutical dosage form comprising: cedaruridine or a pharmaceutically acceptable salt thereof; and azacitidine or a pharmaceutically acceptable salt thereof, in the form of one or more azacitidine mini-tablets.

[0211] Embodiment 46. The pharmaceutical dosage form of embodiment 45, wherein each azacitidine mini-tablet is coated with an enteric coating.

[0212] Embodiment 47. The pharmaceutical dosage form of embodiment 46, wherein the enteric coating comprises polymethacrylate or a copolymer thereof.

[0213] Embodiment 48. The pharmaceutical dosage form of embodiment 46 or 47, wherein the enteric coating is sensitive to pH changes in the intestine.

[0214] Embodiment 49. The pharmaceutical dosage form of any one of embodiments 46 to 48, wherein each azacitidine mini-tablet further comprises a seal coating.

[0215] Embodiment 50. The pharmaceutical dosage form of embodiment 49, wherein the seal coating comprises hydroxypropylmethylcellulose (HPMC).

[0216] Embodiment 51. The pharmaceutical dosage form of any one of embodiments 45 to 50, wherein each azacitidine minitablet comprises about 20% to 50% w / w of azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine minitablet.

[0217] Embodiment 52. The pharmaceutical dosage form of any one of embodiments 45 to 51, wherein each of the azacitidine mini-tablets comprises an inner granular layer and an outer granular layer.

[0218] Embodiment 53. A pharmaceutical dosage form according to embodiment 52, wherein the inner layer of the granule comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

[0219] Embodiment 54. A pharmaceutical dosage form according to embodiment 52 or 53, wherein the outer layer of the granules comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

[0220] Embodiment 55. The pharmaceutical dosage form of any one of embodiments 45 to 54, wherein each azacitidine mini-tablet comprises about 4 mg of azacitidine.

[0221] Embodiment 56. The pharmaceutical dosage form according to any one of embodiments 45 to 65, comprising 8, 9 or 10 azacitidine mini-tablets.

[0222] Embodiment 57. The pharmaceutical dosage form of any one of embodiments 45 to 56, comprising about 32 mg, 36 mg or 40 mg of azacitidine.

[0223] Embodiment 58. The pharmaceutical dosage form according to any one of embodiments 45 to 57, wherein the cedaruridine is formulated for immediate release.

[0224] Embodiment 59. The pharmaceutical dosage form according to any one of embodiments 45 to 58, wherein the cedaruridine is in the form of uncoated mini-tablets, pellets or powder.

[0225] Embodiment 60. The pharmaceutical dosage form of any one of embodiments 45 to 59, wherein the cedaruridine minitablet comprises about 10% to 40% w / w cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine minitablet.

[0226] Embodiment 61. The dosage form of embodiment 60, comprising about 20% w / w of cedaruridine, wherein the weight percentage is relative to the total weight of the uncoated cedaruridine minitablet.

[0227] Embodiment 62. The dosage form of embodiment 60 or 61, further comprising about 40% to 80% w / w lactose monohydrate, about 0.5 to 10% w / w hydroxypropyl methylcellulose (HPMC), about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated cedaruridine minitablets, powder, blend, granules or pellets.

[0228] Embodiment 63. The pharmaceutical dosage form according to any one of embodiments 45 to 62, comprising about 100 mg of cedaruridine.

[0229] Embodiment 64. The pharmaceutical dosage form according to any one of embodiments 51 to 63, further comprising venetoclax.

[0230] Embodiment 65. A capsule comprising the pharmaceutical dosage form according to embodiments 32 to 40.

[0231] Embodiment 66. A capsule comprising azacitidine and cedaruridine, wherein the capsule comprises an enteric-coated capsule shell.

[0232] Embodiment 67. The capsule of embodiment 65 or 66, wherein the enteric-coated capsule shell comprises hydroxypropylmethylcellulose acetate succinate (HPMCAS) and / or hydroxypropylmethylcellulose (HPMC).

[0233] Embodiment 68. The capsule of any one of embodiments 65 to 67, wherein the enteric capsule shell comprises a solid filled in the enteric capsule shell.

[0234] Embodiment 69. The capsule of any one of embodiments 65 to 68, further comprising a buffer salt.

[0235] Embodiment 70. A capsule according to embodiment 69, wherein the buffer salt is selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, 2-amino-2-hydroxymethyl-propane-1,3-diol (tris), sodium hydroxide, sodium citrate, sodium acetate, potassium acetate, citric acid and sodium or potassium citrate, amino acid salts, malic acid and sodium or potassium malate, tartaric acid and potassium or sodium tartrate, glutamic acid and sodium or potassium glutamate, and sodium carbonate.

[0236] Embodiment 71. A capsule as described in any one of embodiments 65 to 70, further comprising about 10% to 50% w / w lactose monohydrate, about 10% to 50% w / w microcrystalline cellulose, about 1% to 20% w / w croscarmellose sodium, about 1% to 10% w / w HPMC, about 1% to 10% w / w silicon dioxide, and about 0.1% to 5% w / w magnesium stearate.

[0237] Embodiment 72. A capsule as described in any one of embodiments 65 to 71, further comprising about 26.2% w / w lactose monohydrate, about 25.7% w / w microcrystalline cellulose, about 8% w / w croscarmellose sodium, about 2% w / w HPMC, about 2.1% w / w silicon dioxide and about 1% w / w magnesium stearate.

[0238] Embodiment 73. The capsule of any one of embodiments 65 to 72, comprising about 5% to 40% w / w azacitidine.

[0239] Embodiment 74. The capsule of any one of embodiments 65 to 73, comprising about 10% w / w azacitidine.

[0240] Embodiment 75. The capsule of any one of embodiments 66 to 74, comprising about 5% to 40% w / w azacitidine.

[0241] Embodiment 76. The capsule of any one of embodiments 66 to 75, comprising about 10% w / w azacitidine.

[0242] Embodiment 77. The capsule of any one of embodiments 65 to 76, further comprising about 5% to 25% w / w sodium phosphate.

[0243] Embodiment 78. The capsule of any one of embodiments 65 to 77, further comprising about 15% w / w sodium phosphate.

[0244] Embodiment 79. A method of treating cancer in a patient, comprising administering to a patient in need thereof a dosage form according to any one of embodiments 1 to 64 or a capsule according to any one of embodiments 65 to 78.

[0245] Embodiment 80. The method of embodiment 79, wherein the cancer is leukemia.

[0246] Embodiment 81. The method of embodiment 79, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumors (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

[0247] Embodiment 82. The method of any one of embodiments 79 to 81, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

[0248] Embodiment 83. The method of any one of embodiments 79 to 82, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

[0249] Embodiment 84. The method of any one of embodiments 79 to 83, further comprising another therapeutic agent.

[0250] Embodiment 85. The method of embodiment 84, wherein the additional therapeutic agent is one or more selected from the list consisting of ADI-PEG 20, AMG-176, APG-115, APR-246, avelumab, bendamustine, bisantrene, berentuzumab vedotin, capecitabine, CB-839, cisplatin, CS-01, gutuzumab, cyclophosphamide, cytarabine, dasatinib, daunomycin, DCLL9718S, decitabine, deferasirox, dexamethasone, durvalumab, eltrombopag, inanib, entinostat, Entrectinib, enzalutamide, icadolstat, erythropoietin, etoposide, ivoparcept, filgrastim, fludarabine phosphate, flumatinib, gemcitabine, gemtuzumab ozogamicin, gilteritinib, GM-CSF, GSK2879552, HMPL-523, homoharringtonine, IBI188, ibrutinib, idarubicin, itatinib, ivosidenib, jacotinib, KPT-8602 , LDE255, lenalidomide, lirilumab, LP-108, magrilimab, MAX-40279, mitoxantrone, mitoxantrone liposome, mosetinib, moxifloxacin, nivolumab, olutanib, omacitaxin, oxaliplatin, paclitaxel, pembrolizumab, pavostat, pinostat, prespastat, quizartinib, revelimid, regresent, rituximab, romidepsin, RP 7214, S64315, S65487, sabatolizumab, celide, selumetinib, sredrin, sirolimus, SL-401, SNDX-5613, sorafenib, talazopanib, tamibarotene, torinapan, trastuzumab, toxistat, tyrosine kinase inhibitors, Uproleselan, Velcade, venetoclax, vincristine, vesiculomab, vorinostat, and worzarocin.

[0251] Embodiment 86. The dosage form of any one of embodiments 1 to 64 or the capsule of any one of embodiments 65 to 78 for use in treating cancer.

[0252] Embodiment 87. The dosage form of any one of embodiments 1 to 64 or the capsule of any one of embodiments 65 to 78 for use in the manufacture of a medicament for the treatment of cancer.

[0253] Embodiment 88. The dosage form of embodiment 87, wherein the cancer is leukemia.

[0254] Embodiment 89. The dosage form of embodiment 87, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumor (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

[0255] Embodiment 90. The dosage form of any one of embodiments 86 to 89, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

[0256] Embodiment 91. The dosage form of any one of embodiments 86 to 90, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

[0257] Embodiment 92. Use of a dosage form according to any one of embodiments 1 to 64 or a capsule according to any one of embodiments 65 to 78 for treating cancer.

[0258] Embodiment 93. Use of a dosage form according to any one of embodiments 1 to 64 or a capsule according to any one of embodiments 65 to 78 for the manufacture of a medicament for treating cancer.

[0259] Embodiment 94. The use according to embodiment 92 or 93, wherein the cancer is leukemia.

[0260] Embodiment 95. The use of embodiment 92 or 93, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumors (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

[0261] Embodiment 96. The use of any one of embodiments 92 to 95, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), and previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML).

[0262] Embodiment 97. The use according to any one of embodiments 92 to 96, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

[0263] Embodiment 98. A combination for the treatment of cancer, wherein the combination comprises cedaruridine or a pharmaceutically acceptable salt thereof; and azacitidine or a pharmaceutically acceptable salt thereof, wherein the cedaruridine is formulated for immediate release; and the azacitidine is formulated for modified release and is provided as a delayed release mini-tablet.

[0264] Embodiment 99. A capsule comprising azacitidine, wherein the capsule comprises an enteric coated capsule shell.

[0265] Embodiment 100. The capsule of embodiment 99, further comprising cedaruridine.

[0266] Embodiment 101. The capsule of embodiment 99 or 100, wherein the enteric-coated capsule shell comprises hydroxypropylmethylcellulose acetate succinate (HPMCAS) and / or hydroxypropylmethylcellulose (HPMC).

[0267] Embodiment 102. The capsule of embodiments 99 to 101, wherein the enteric capsule shell comprises a solid filled in the enteric capsule shell.

[0268] Embodiment 103. The capsule of embodiments 99 to 102, further comprising a buffer salt.

[0269] Embodiment 104. A capsule according to embodiment 103, wherein the buffer salt is selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, 2-amino-2-hydroxymethyl-propane-1,3-diol (tris), sodium hydroxide, sodium citrate, sodium acetate, potassium acetate, citric acid and sodium or potassium citrate, amino acid salts, malic acid and sodium or potassium malate, tartaric acid and potassium or sodium tartrate, glutamic acid and sodium or potassium glutamate, and sodium carbonate.

[0270] Embodiment 105. The capsule of embodiments 99 to 104, further comprising about 10% to 50% w / w lactose monohydrate, about 10% to 50% w / w microcrystalline cellulose, about 1% to 20% w / w croscarmellose sodium, about 1% to 10% w / w HPMC, about 1% to 10% w / w silicon dioxide, and about 0.1% to 5% w / w magnesium stearate.

[0271] Embodiment 106. The capsule of embodiments 99 to 105, further comprising about 26.2% w / w lactose monohydrate, about 25.7% w / w microcrystalline cellulose, about 8% w / w croscarmellose sodium, about 2% w / w HPMC, about 2.1% w / w silicon dioxide, and about 1% w / w magnesium stearate.

[0272] Embodiment 107. The capsule of embodiments 99 to 106, comprising about 5% to 40% w / w azacitidine.

[0273] Embodiment 108. The capsule of embodiments 99 to 107, comprising about 10% w / w azacitidine.

[0274] Embodiment 109. The capsule of embodiments 100 to 108, comprising about 5% to 40% w / w cedaruridine.

[0275] Embodiment 110. The capsule of any one of embodiments 100 to 109, comprising about 10% w / w cedaruridine.

[0276] Embodiment 111. The capsule of embodiments 99 to 110, further comprising about 5% to 25% w / w sodium phosphate.

[0277] Embodiment 112. The capsule of embodiments 99 to 111, further comprising about 15% w / w sodium phosphate.

[0278] Embodiment 113. A method of treating cancer in a patient, comprising administering the capsule of any one of Embodiments 99 to 112 to a patient in need thereof.

[0279] Embodiment 114. The method of embodiment 113, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), and previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML).

[0280] Embodiment 115. The method of embodiment 113 or 114, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

[0281] Embodiment 116. The capsule according to embodiments 99 to 112, for use in treating cancer. Example

[0282] The following examples are included to demonstrate specific embodiments of the present disclosure. It will be appreciated by those skilled in the art that the techniques disclosed in the subsequent examples represent techniques that can function well in the practice of the present disclosure, and therefore can be considered to constitute a specific mode of its practice. However, it will be appreciated by those skilled in the art that many changes can be made in the disclosed specific embodiments without departing from the spirit and scope of the present disclosure and still achieving similar or similar results, according to the present disclosure. Example 1: Coated FDC cedaruridine and azacitidine tablets

[0283] Both azacitidine and cedaruridine were formulated for modified release. 20 mg azacitidine and cedaruridine fixed dose combination (FDC) oval tablets with a core tablet weight of 500 mg (Table 1) were seal coated first, followed by coating with 70 / 30 ratio of HPMC pore former as functional coating to achieve 12% and 15% coating weight gain. The compositions of the coatings are listed in Tables 1-2 and 1-3, respectively. PK studies were conducted on 12% and 15% weight gain modified release tablets. Table 1-1: Composition of oval FDC tablets containing 20 mg of cedaruridine and 20 mg of azacitidine Table 1-2: Seal coating composition (200 mL formulation, 10% solids) Table 1-3: 70:30 Composition (2000 mL formulation, 10% solids) *Surelease dispersion at 25% solids Manufacturing Process

[0284] Azacitidine, chiduridine and all intragranular excipients were dispensed into separate containers and manually screened through a 30 mesh. The screened azacitidine, chiduridine and intragranular excipients except magnesium stearate were added to a Turbula T2 blender of appropriate capacity and mixed at 25 rpm for 15 minutes. Then, intragranular magnesium stearate was screened and added to the blend and lubrication blended in a Turbula T2 mixer blender at 25 rpm for 3 minutes.

[0285] The intragranular blend was then roller compacted into ribbons and the ribbons were milled into granules. The milled granules were blended with screened extragranular excipients to make the final blend. The final blend was compressed into tablets using oval tools in a Ronchi single eccentric tablet press. The target weight of the tablets was 500 mg ± 10%.

[0286] The uncoated tablets were seal coated at 1% weight gain followed by a functional coating of Surelease to adjust the dissolution profile. Complete coating system YS-1-19025-A-Clear) HPMC is used as both seal coat and ethylcellulose dispersion The pore-forming agent in the seal-coated tablet is used for functional coating. The pore former was applied at 12% and 15% weight gain. Coating was done in a pan coater. Dissolution curve

[0287] The coated FDC tablets (with 12% and 15% weight gain) were tested for dissolution in 500 mL, pH 6.8, 50 mM sodium phosphate buffer at 37°C bath temperature with a stirring speed of 75 rpm in a basket. Drug release data were collected at 250 rpm at 30, 60, 90, 120, 180, 300 minutes and infinity at 315 minutes. The drug release profile of azacitidine is shown in Figure 1 middle. Example 2: Manufacturing process of uncoated cedaruridine 20 mg tablets and coated / uncoated azacitidine 5 mg small tablets

[0288] Azacitidine and cedaruridine were screened through 30 mesh and pre-blended with all excipients listed in Tables 2-1 and 2-2 except magnesium stearate. Magnesium stearate was then screened and added to the blend and blended. The final blend was compressed into 0.25 inch round tablets by direct compression. The target weight of the tablets was 100 mg ± 7.5 mg. Table 2-1: Sidacrudine 20 mg uncoated tablets Table 2-2: Azacitidine 5 mg small tablets Element mg % Azacitidine 5.0 5.0 Lactose monohydrate (FlowLac 90) 86.0 86.0 Cross-linked sodium carboxymethyl cellulose (Ac-di-sol SD-711) 5.0 5.0 Hydroxypropyl methylcellulose E5 2910 2.0 2.0 Colloidal Silica 1.0 1.0 Magnesium stearate (Hyqual, Vegetal) 1.0 1.0 total 100 100

[0289] A portion of the azacitidine mini-tablets were first seal coated at 2% weight gain followed by coating at a ratio of 70:30 Functional coating with pore former. Opadry Complete Coating System YS-1-19025-A-Clear from Colorcon was used for both seal coating and as a pore former in an ethylcellulose dispersion (Surelease) for functional coating. The seal coated azacitidine mini-tablets were further coated with an enteric coating with 12% weight gain Surelease / HPMC pore former. The coating was performed in a pan coater. The compositions of the seal coating and enteric coating are listed in Tables 2-3 and 2-4. Table 2-3: Seal coating composition for azacitidine mini-tablets Table 2-4: Enteric coating for azacitidine mini-tablets (pH insensitive) Dissolution profile of azacitidine

[0290] Coated and uncoated azacitidine mini-tablets were tested for dissolution testing. Dissolution data were collected by placing four (4) coated or uncoated azacitidine mini-tablets (5 mg) in a size 0 HPMC capsule (Vcap plus). Dissolution testing was performed in 500 mL, pH 6.8, 50 mM sodium phosphate buffer at a bath temperature of 37°C in a basket with a stirring speed of 75 rpm. Drug release data were collected at 250 rpm at 15, 30, 45, 60, 90, 105 and 120 minutes (considered as infinity). The release data of azacitidine was Figure 2 middle.

[0291] like Figure 2 As shown in , the uncoated 4 azacitidine mini-tablets (20 mg in total) showed real-time release with >85% release within 30 minutes, while the coated azacitidine mini-tablets had a lag time of 30 minutes followed by complete release at 90 minutes.

[0292] For the combination of coated and uncoated azacitidine tablets in capsules, the dissolution profile of the combination of 2 uncoated azacitidine mini-tablets and the remaining 2 coated azacitidine mini-tablets was tested under the same conditions. Drug release data were collected at 15, 30, 45, 60, 90 and 105 minutes. The release data of azacitidine are shown in Figure 3 middle.

[0293] Figure 4 The dissolution release profiles of azacitidine from dosage forms comprising coated and uncoated azacitidine mini-tablets at a ratio of 1:1 and 1:2 (uncoated:coated) at pH 6.8 are shown. Figure 4 As shown in , the dosage form with more coated azacitidine mini-tablets exhibited more delayed release of azacitidine. Example 3: Uncoated 20 mg cedaruridine tablets and 4 mg azacitidine (inner granule layer and outer granule layer) small tablets Manufacturing Process

[0294] 20 mg of cedaridine round tablets were prepared by direct compression. The composition of the cedaridine tablet core is presented in Table 3-1. The individual excipients and cedaridine except magnesium stearate were screened through a 30 mesh and blended in a 1.5L V-blender at 25 rpm for 15 minutes. The blended cedaridine and excipients were then mixed with manually screened magnesium stearate and blended again at 25 rpm for 3 minutes. The final blend was compressed into round (0.25" inch) tablets by direct compression on a Korsch XL-100 press. The cedaridine tablets were uncoated and used as immediate release mini-tablets. Table 3-1: Composition of 20 mg cedar uridine tablets

[0295] Azacitidine mini-tablets having an inner granular layer and an outer granular layer having two different compositions of Table 3-2 ("Core 1" and "Core 2") were prepared. Azacitidine and all intragranular excipients were dispensed into separate containers and screened through a 30 mesh. The screened azacitidine and intragranular excipients except magnesium stearate were added to a blender with an appropriate capacity and mixed at 25 rpm for a predetermined duration. Then, magnesium stearate for the inner granular layer was screened and added to the blend, and lubrication blending was performed. The intragranular blend was then roller compacted into a ribbon and the ribbon was milled into granules. The milled granules were mixed with screened additional granular excipients to make the final blend. The final blend was compressed into mini-tablets using a 2.5-mm round flat tool. The target weight of the tablet was 10 mg ± 10% and the target hardness range was between 1 and 3 kp. Table 3-2: Tablet composition of 4 mg azacitidine small tablets

[0296] The uncoated tablets were seal coated at 5% weight gain followed by a functional coating of Surelease to adjust the dissolution profile. HPMC in the complete coating system YS-1-19025-A-Clear) was used both as a seal coat and as a pore former in an ethylcellulose dispersion (Surelease) for the functional coating. "Core 1" mini-tablets were coated at 20% weight gain with 75:25 ( The "core 2" tablets were coated with 80:20 Surelease:pore former at 15% weight gain. The composition of the coating is listed in Tables 3-3 and 3-4. The seal coating and functional coating of the tablets were performed in a Wuster coater. Table 3-3: Seal coating composition (200 mL formulation, 10% solids) Table 3-4: Surelease composition (500 mL formulation, 10% solids) *Surelease dispersion at 25% solids Dissolution curve

[0297] For dissolution testing, five (5) coated or uncoated azacitidine mini-tablets at each weight gain (15% and 20%) were placed in size 0, VCAPS Plus capsules to achieve a total dose of 20 mg and tested for dissolution. Dissolution testing was performed in 500 mL, pH 6.8, 50 mM sodium phosphate buffer at 37°C bath temperature in a basket with a stirring speed of 75 rpm. Drug release data were collected at 0, 30, 45, 60, 90, 120, 180 minutes and at 195 minutes (considered as infinity) at a speed of 250 rpm. Release profiles for all 3 groups are presented in Figure 6 middle.

[0298] like Figure 6 As shown in FIG. 1 , the dissolution results show that the uncoated azacitidine mini-tablets released azacitidine within 30 minutes, followed by the azacitidine mini-tablets coated with 15% of the 80 / 20 Surelease: pore former ratio and then the azacitidine mini-tablets coated with 20% of the 75 / 25 Surelease: pore former ratio. The drug release of the 15% and 20% coated mini-tablets was extended to 90 minutes and 120 minutes, respectively. Example 4: Uncoated 20 mg cedaruridine tablets and 3-layer coated 4 mg azacitidine (inner and outer granule layers) small tablets Manufacturing method

[0299] Uncoated cedaruridine 20 mg mini-tablets and uncoated azacitidine 4 mg mini-tablets were prepared using the method described in Example 3. The compositions of cedaruridine and azacitidine mini-tablets are shown in Tables 4-1 and 4-2. Table 4-1: Composition of 20 mg cedaridine tablets Table 4-2: Composition of 4 mg azacitidine small tablets

[0300] The uncoated azacitidine mini-tablets were seal coated at 2% WG, followed by a mid-coat at 20% WG, and a 5.3% WG of both polymers. The final coating of polymer corresponded to a total weight gain of 8.5%.

[0301] The seal coating and functional coating of the small tablets were both carried out in a Wuster coater. The compositions of the seal coating, intermediate coating and functional coating are presented in Tables 4-3, 4-4 and 4-5, respectively. Table 4-3: Composition of 2% Weight Gain Seal Coat Table 4-4: Composition of 20% weight gain intermediate coating Table 4-5: Composition of enteric functional coating Dissolution testing

[0302] For dissolution testing, five (5) mini-tablets of coated azacitidine at 5.3% polymer weight gain were placed in size 1, VCAPS plus capsules for a total dose of 20 mg and tested for dissolution.

[0303] Dissolution testing was performed in two stages (acid stage, pH 1.2, 0.1 N HCl and buffer stage, pH 6.8, 50 mM phosphate buffer) at a bath temperature of 37°C in a basket and 500 mL of dissolution medium with a stirring speed of 75 rpm. The small tablet of polymer prevented the release of azacitidine in the acid phase, followed by rapid release in the buffer phase at pH 6.8 after the medium switch at 120 min ( Figure 7 ).like Figure 7 As shown in Figure 2, azacitidine was not released in the first 2 hours under acidic conditions, but most of azacitidine was released after reaching pH 6.8, confirming that pH sensitivity of L30D coating. In addition, 5.3% weight gain The coated mini-tablets provided adequate protection in the acid phase, followed by rapid release in the buffer phase after medium switch at pH 6.8 at 120 minutes. Example 5-1: Uncoated 20 mg cedaruridine tablets and double-coated 4 mg azacitidine (inner and outer granule layers) small tablets

[0304] The uncoated cedaruridine 20 mg tablets of Example 4 are provided. Azacitidine and all intragranular excipients except magnesium stearate listed in Table 5-1 are dispensed into an 8Qt.V Shell equipped on a PK blender and mixed at 25 rpm for 10 minutes. The pre-blend is screened through a Quadro Comil model U3 equipped with a 032R screen and a circular impeller at a speed of 4500+ / -100 rpm. The screened material is transferred back to the blender and mixed again at 25 rpm for 10 minutes. Magnesium stearate is manually screened through a 30 mesh and added to the blender and mixed at 25 rpm for 10 minutes. The intragranular blend is roller compacted on an Alexanderwerk roller compactor at a roller speed of 4.0 rpm, a compaction force of 4.0 KN / cm, and a feed screw speed of 20 rpm. The ribbon is milled on a granulator equipped with a 0.80 mm screen at a speed of 100 rpm. The extragranular excipient dosage is adjusted based on the yield of the intragranular milled particles. The extragranular excipients are manually screened through 30 meshes. The intragranular milled particles and the extragranular excipients except magnesium stearate are transferred to a blender and mixed at 25rpm for 10 minutes. The screened magnesium stearate is added to the blended material and mixed at 25rpm for 3 minutes. The final blend is compressed into small tablets using a round tool of 2.5mm diameter on a Natoli RD30 press. The target weight of the small tablet is 10mg±1.0mg and the hardness is 1 to 3KP, measured by the hardness tester (Testor) of Scotax. Table 5-1: Azacitidine 4 mg uncoated small tablets

[0305] The uncoated azacitidine 4 mg mini-tablets were coated with the ingredients listed in Tables 5-2 and 5-3 using the method described in Example 2. A weight gain of 15% or 20% was used. Table 5-2: Seal coating composition Element % Opadry Clear, YS-1-19025-A (HPMC based) 10 Pure water 90 Table 5-3: Modified Release Coatings

[0306] Dissolution profiles of coated azacitidine mini-tablets (15% and 20% weight gain) were measured using the method described in Example 2. Drug release data were collected at 0, 30, 45, 60, 90, 120, 180 minutes and at 195 minutes (considered as infinity). Figure 5The dissolution release profile of azacitidine at pH 6.8 is shown. Example 5-2: Uncoated 20 mg cedaruridine tablets and 3-layer coated 4 mg azacitidine (inner and outer granule layers) small tablets

[0307] Instead of coating as described in Example 5-1, uncoated azacitidine 4 mg mini-tablets comprising an inner granule layer and an outer granule layer were seal-coated in two layers using the ingredients listed in Tables 5-4 (first layer) and 5-5 (second layer). The seal-coated azacitidine pellets were further coated with a delayed release coating using the ingredients listed in Table 5-6. Table 5-4: Seal coating first layer Element % HPMC E5 7.5 Pure water 92.5 Table 5-5: Second seal coating layer Element % HPMC E3 7.5 Light magnesium oxide 7.5 Pure water 85 Table 5-6: Delayed release coating Example 6: Uncoated 20 mg cedaruridine tablets and double-coated 4 mg azacitidine (inner granule layer and outer granule layer) small tablets Manufacturing Process

[0308] 20 mg of cedaridine round tablets were prepared by direct compression. The composition of the cedaridine core tablets is listed in Table 6-1. The individual excipients and cedaridine except magnesium stearate were screened through a 30 mesh and blended in a 1.5L V-blender for 15 to 20 minutes. The blended cedaridine and excipients were then mixed with the screened magnesium stearate and blended again in the V-blender for 5 minutes. The cedaridine tablets were compressed into round (0.25" inch) tablets by direct compression on a Korsch XL-100 press. Table 6-1: Composition of 20 mg cedaruridine tablets

[0309] Azacitidine and all intragranular excipients were distributed in separate containers and screened through 30 meshes. The composition of azacitidine tablet core tablets is listed in Table 6-2. The sieved azacitidine and the intragranular excipients except magnesium stearate were added to a 5L Bohle blender and mixed at 25rpm for 10 minutes. Then, magnesium stearate was sieved, and added to the blend, and lubricated and blended at 25rpm for 3 minutes in a 5L Bohle blender. The intragranular blend was rolled compacted into ribbons on Gereteis FMX1064 and the ribbons were milled into particles. The milled particles were blended at 25rpm for 10 minutes with the screened extragranular excipients except magnesium stearate in the same 5L Bohle blender. The screened magnesium stearate was added to the remainder of the blender and mixed again at 25rpm for 3 minutes. The final blend was compressed into small tablets using 2.5-mm round flat tooling. The target weight of the tablets was 10 mg ± 10% and the target hardness ranged between 1 and 3 kp. Table 6-2: Azacitidine 4 mg uncoated small tablets

[0310] The uncoated tablets were seal coated at 2% weight gain, followed by Functional coating of polymer (L30D-55) at 4.0% polymer weight gain. Sealing and functional coating of small tablets were performed in a 3L Wurster coater GPCG2. The compositions of the seal coating and enteric coating are presented in Tables 38 and 40, and the process parameters are presented in Tables 6-3 and 6-4. Table 6-3: Azacitidine seal coating composition Element Suppliers Amount (g) HPMC E3 Viva Pharma 12 PEG 600 TCI 12 Pure water 162.8 Total dispersion 176.8 Table 6-4: Composition of azacitidine functional coating Dissolution testing

[0311] For dissolution testing, five (5) coated azacitidine mini-tablets at 4.0% polymer weight gain were placed in size 1, VCAP plus capsules to achieve a total dose of 20 mg and tested for dissolution. Dissolution testing was performed in two phases (acid phase, pH 1.2, 0.1N HCl and buffer phase, pH 6.8, 50 mM phosphate buffer) at a bath temperature of 37°C in a basket and 500 mL of dissolution medium at a stirring speed of 75 rpm. Figure 8 As shown in Small tablets of polymer prevented azacitidine release in the acid phase, followed by rapid release in the buffer phase, pH 6.8, after the medium switch at 120 minutes. Example 7: Uncoated 100 mg cedaruridine tablets and coated 4 mg azacitidine small tablets

[0312] Using the method described in Example 6, uncoated cedaruridine 100 mg tablets were prepared using the ingredients listed in Table 7-1. Coated Azacitidine 4 mg mini-tablets. Table 7-1: Sidacrudine 100 mg uncoated tablets Element mg % Sidacrudine 100.00 20.00 Lactose monohydrate 357.50 71.50 Croscarmellose Sodium 25.00 5.00 Hydroxypropyl methylcellulose 10.00 2.00 Colloidal Silica 5.00 1.00 Magnesium Stearate 2.50 0.50 total 500.00 100.00 Table 7-2: Composition of 4 mg Azacitidine Mini Tablets with Coating

[0313] For the dissolution test, 100 mg uncoated cedaruridine tablets were placed in No. 0, Plus capsules and tested for dissolution. The dissolution test was performed in a basket and 900 mL of dissolution medium at a bath temperature of 37°C in two stages (acid stage pH 1.2, 0.1 N HCl and buffer stage pH 6.8, 50 mM phosphate buffer) with a stirring speed of 75 rpm, wherein the switch occurred at 120 minutes. The drug release data were collected at 0, 15, 30, 60, 90, 120 hours and at 135 minutes (considered as infinity). The release curves are presented in Fig. 9 In. Fig. 9 As shown in , the uncoated cedaruridine tablets were completely dissolved in the acid phase within about 30 minutes before the medium switch.

[0314] For dissolution testing, five (5) enteric coated azacitidine mini-tablets were placed in No. 0, Plus capsules and tested for dissolution. Dissolution testing was performed in two phases (acid phase, pH 1.2, 0.1N HCl and buffer phase, pH 6.8, 50 mM phosphate buffer) at a bath temperature of 37°C in a basket and 500 mL of dissolution medium at a stirring speed of 75 rpm. The small tablet of polymer prevented the release of azacitidine in the acid phase, followed by rapid release in the buffer phase 6.8 pH after the medium switch at 120 minutes. Drug release data were collected at 0, 60, 120, 135, 150, 165, 180 minutes and at 195 minutes (considered as infinity). The release curves are presented in Fig.10 In. Fig.10 As shown in Small tablets of polymer prevented the release of azacitidine in the acid phase followed by rapid release in the buffer phase 6.8 pH after the medium switch at 120 minutes.

[0315] To test the dissolution of enteric-coated azacitidine mini-tablets at various pH values, five (5) enteric-coated azacitidine mini-tablets were placed in a 0, Plus capsules and tested for dissolution. Dissolution testing was performed in 6 groups at 37°C bath temperature in a basket with a stirring speed of 75 rpm in each of pH 2.3, 3.0, 4.5, 5.2, 5.5 and 6.0 buffers. Drug release data were collected at 250 rpm at 0, 15, 30, 45, 60, 90 and 120 minutes (considered as infinity). Release curves for all 6 groups are presented in Fig.11 In. Fig.11 As shown in Example 8: Preparation of blended cedaruridine powder

[0316] A cedaridine blend powder having the composition of Table 8-1 is prepared and can be optionally used in capsules instead of uncoated cedaridine tablets. Cedaridine and all other excipients except magnesium stearate are manually screened through a 30 mesh and transferred to a 5L Bohle blender and mixed at 25 rpm for 10 minutes. Magnesium stearate is manually screened through a 30 mesh and transferred to a blender and mixed with the drug and other excipients at 25 rpm for 3 minutes. The cedaridine powder blend formulation can be filled in capsules. Table 8-1 Example 9: Preparation of capsules containing the combination of Example 7

[0317] Place an uncoated 100 mg cedaruridine tablet (from Example 7) and ten 4 mg azacitidine coated mini-tablets (from Example 7) on a The resulting capsules had the composition listed in Table 9. Table 9: Composition of Azacitidine 40 mg / Cedacuridine 100 mg Capsules Example 10: Preparation of capsules containing cedaruridine powder and coated azacitidine mini-tablets

[0318] 100 mg of the cedar uridine powder of Example 8 and ten coated 4 mg azacitidine small tablets of Example 7 were placed For the dissolution test, 100 mg of cedar uridine powder was placed in No. 0, Plus capsules and tested for dissolution. The dissolution test was performed in a basket and 900 mL of dissolution medium at a bath temperature of 37°C in two stages (acid stage pH 1.2, 0.1 N HCl and buffer stage pH 6.8, 50 mM phosphate buffer) with a stirring speed of 75 rpm, wherein the switch occurred at 120 minutes. The drug release data were collected at 0, 30, 45, 60, 90, 120, 180 minutes and at 195 minutes (considered as infinity).

[0319] For the dissolution test, the enteric-coated azacitidine mini-tablets were placed in No. 0, Plus capsules and tested for dissolution. The dissolution test was performed in a basket and 500 mL of dissolution medium at a bath temperature of 37°C in two stages (acid stage pH 1.2, 0.1 N HCl and buffer stage pH 6.8, 50 mM phosphate buffer) with a stirring speed of 75 rpm. Drug release data were collected at 0, 30, 45, 60, 90, 120, 180 minutes and at 195 minutes (considered as infinity). Example 11: Enteric-coated capsules filled with azacitidine and cedaruridine

[0320] About 8 to 10 gram batches of the cedaruridine and azacitidine powder mixture were prepared and filled into capsule shells. The composition of the powders is provided in the table below.

[0321] Chiduridine and azacitidine in powder form, galactose monohydrate, half PH-102 and the remaining excipients except magnesium stearate were sieved through a 0.6-mm sieve and transferred into an 8-oz container.

[0322] The remaining lactose monohydrate and PH-102 is used for dry cleaning of containers of cedaruridine and decitabine. Half of the total amount of PH-102 and lactose monohydrate was used for dry washing. After dry washing, both excipients were screened through a 0.6-mm sieve and added to the blend container. Pre-blending of the mixture was performed in a Turbula shaker at 25 rpm for 15 minutes, followed by sieving through a 0.6-mm sieve and further blending for 15 minutes at 25 rpm. The weight of the resulting blend was weighed and used to adjust the amount of magnesium stearate, which was manually sieved through a 0.6-mm sieve. The sieved magnesium stearate was then added to the blend and blended for 3 minutes at 25 rpm.

[0323] The final blend was manually filled into the capsules at a predetermined fill weight of 200 mg ± 3 mg per capsule. Enteric coated capsule shell (purchased from Capsugel).

[0324] The capsules were packaged in 30-cc white HDPE bottles with 2 x 1-g desiccant canisters in a count of 8 per bottle. The bottles were capped with 28-mm child-resistance closures and induction sealed.

[0325] The ingredients and weight ratios of capsules containing 20 mg azacitidine and 20 mg cedaruridine are provided in Table 11 below. Table 11: 20 mg Azacitidine / 20 mg Cedacurid FDC Capsules Example 12: FDC cedaruridine and azacitidine tablets

[0326] Both azacitidine and chiduridine were formulated for immediate release. Using the method described in Example 1, 20 mg azacitidine and chiduridine fixed dose combination (FDC) oval tablets had a core tablet weight of 500 mg (Table 12). Table 12: Composition of oval FDC tablets containing 20 mg cedaruridine and 20 mg azacitidine Example 13: Pharmacokinetic (PK) study in monkeys using the dosage form of Example 1

[0327] Twelve monkeys were divided into three groups, 4 monkeys in each group, and given the following doses: Group 1 - uncoated 20 mg cedaruridine / 20 mg azacitidine tablets as control; Group 2 - 12% weight gain coated tablets; and Group 3 - 15% weight gain coated tablets, orally through a gavage tube into the stomach, once a day. Blood samples (about 0.8 mL) were collected before dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after dosing on days 1 and 2. The PK data of the collected blood samples were evaluated. The PK data of azacitidine are presented in Tables 13-1 and 13-2 and Fig.12 middle. Table 13-1: Azacitidine AUC 0-inf Table 13-2: Azacitidine C max data

[0328] The data show that the (Ethylcellulose) coating can be used to modify the release profile of azacitidine. Fig.12As shown in Tables 13-1 and 13-2, the coated tablets with 12% and 15% weight gain resulted in lag times of 30 minutes to 1.5 hours, respectively. Drug release from the 12 to 15% coated tablets was extended to 4 to 5 hours versus 30 minutes for the uncoated tablets. The 12% and 15% coated tablets did not perform as well as the uncoated tablets in the PK study. As shown in Tables 13-1 and 13-2, the 15% weight gain tablets performed worse than the 12%. The decrease in AUC and Cmax may be a result of the longer lag time of 4 to 5 hours and extended release for the 12% and 15% coated tablets. Example 14: Pharmacokinetic (PK) study in monkeys using the combination of Example 2

[0329] Two different doses of azacitidine, 20 mg and 30 mg, were tested in monkeys to evaluate pharmacokinetics (PK), with 10 mg delivered as immediate release and the remaining azacitidine dose delivered as delayed release.

[0330] PK data in monkeys were collected on two different dose levels of azacitidine - 12% weight gain coated mini-tablets at 20 mg and 30 mg, and uncoated cedaruridine mini-tablets. 50% or 33% of the total azacitidine dose was given as immediate release and the remaining dose was given as delayed release. Control group 1 contained uncoated azacitidine and cedaruridine at a dose of 20 mg. The dosing groups for this PK study were as follows:

[0331] Group 1 (control): 20 mg cedaruridine, immediate release + 20 mg azacitidine, immediate release. Group 2: 20 mg cedaruridine, immediate release + 10 mg azacitidine, immediate release + 10 mg azacitidine, modified release: Group 3: 20 mg cedaruridine, immediate release + 10 mg azacitidine, immediate release + 20 mg azacitidine, modified release: Table 14-1 shows the dosing schedule. Table 14-1: Dosing groups used in PK studies

[0332] Tables 14-2 and 14-3 provide data on Day 1 and Day 2 of this study. Table 14-2: Azacitidine AUC 0-inf *Including outliers Table 14-3: Azacitidine C max data *Including one outlier

[0333] Fig.13The mean cedaruridine concentration-time curves of the three groups on day 1 and day 2 are shown. Fig.14 The mean azacitidine concentration-time curves for the three groups are shown on days 1 and 2. Azacitidine round mini-tablets containing 5 mg azacitidine with pore former (70:30) extended the release of drug to 90 minutes. Delivery of cedaruridine in immediate release and delivery of azacitidine in a combination of immediate release and modified release can improve bioavailability and exposure. On day 2, the plasma concentration of azacitidine in Group 2, where the 20 mg azacitidine dose was delivered with 50% immediate release and 50% modified release, was slightly lower compared to the plasma concentration of azacitidine in the control group. However, the plasma concentration of Group 3, 30 mg azacitidine dose, had higher plasma concentrations compared to the control group, where 33% of the azacitidine dose was delivered with immediate release and 67% of the azacitidine dose was delivered with modified release. Example 15: Pharmacokinetic (PK) study in monkeys using the combination of Example 3

[0334] In this study, azacitidine was delivered as delayed release only at three different dose levels of 20 mg, 32 mg, and 40 mg and two (2) different coating weight gains (15%, 20%). The cedaruridine dose was kept constant at 20 mg in all groups and delivered as immediate release as described in Example 3. In this round of PK studies, azacitidine was delivered as mini-tablets contained in HPMC capsules. Each mini-tablet contained 4 mg of azacitidine as described in Example 3. This PK study was divided into two parts to accommodate the 3 different azacitidine doses and two different coating weight gains. Dosing Groups in PK Studies

[0335] The structural design of the different dosing groups of this PK study is summarized below and in Table 15-1. This PK study was divided into two parts based on the drug release data of two different coating weight gains. The azacitidine dose was gradually increased from 20 mg to 40 mg between groups. Cidaruciidine was delivered in real-time release at a dose of 20 mg. Part 1 of the PK study, a total of 4 groups (faster release)

[0336] Group 1 (Control): 20 mg cedaruridine, immediate release + 20 mg azacitidine, immediate release. Group 2: 20 mg cedaruridine, immediate release + 20 mg azacitidine, coated at 15% WG 80 / 20. Group 3: 20 mg cedaruridine, immediate release + 32 mg azacitidine, coated at 15% WG 80 / 20. Group 4: 20 mg cedaruridine, immediate release + 40 mg azacitidine, coated at 15% WG 80 / 20. Part 2 of PK Study, 4 Groups Total (Slower Release)

[0337] Group 1 (Control): 20 mg cedaruridine, immediate release + 20 mg azacitidine, immediate release. Group 5: 20 mg cedaruridine, immediate release + 20 mg azacitidine, coated at 20% weight gain 75 / 25. Group 6: 20 mg cedaruridine, immediate release + 32 mg azacitidine, coated at 20% weight gain 75 / 25. Group 7: 20 mg cedaruridine, immediate release + 40 mg azacitidine, coated at 20% weight gain 75 / 25. Table 15-1: Dosing groups in Part 1 and Part 2 PK studies Part 1 PK studies

[0338] PK data in monkeys were collected for 15% and 20% coated mini-tablets at three different dose levels of azacitidine 20 mg, 32 mg, and 40 mg, and uncoated cedaruridine tablets. Control group 1 contained uncoated azacitidine and cedaruridine at a dose of 20 mg. Part 1 of the PK study was conducted using 15% weight gain coated mini-tablets. The PK data for Part 1 of the study are presented in Tables 15-2 and 15-3 and Fig.15 Based on the collected PK data from Part 1 of this study, the mean exposure of Group 2 was equivalent to that of Control Group 1 at the same dose of azacitidine, however, 2 of the 3 animals showed much lower exposures. The higher doses of 30 mg and 40 mg help compensate for the loss of absorption of the coated mini-tablets. Table 15-2: Azacitidine AUC for 15% Weight Gain Coated Mini Tablets at 80 / 20 Ratio 0-inf (Part 1 PK study) Table 15-3: Azacitidine C at 15% weight gain coated mini tablets at 80 / 20 ratio max Data (Part 1 PK study) Part 2 PK studies

[0339] The 20% weight gain coated mini-tablets were used in Part 2 of the PK study. The PK data for Part 2 of this study are in Tables 15-4 and 15-5. Fig.16The mean concentration profiles of azacitidine for the 20% weight gain coated mini-tablets at a 75 / 25 ratio are shown. For Group 5, where the same dose of azacitidine 20 mg was provided in a delayed release manner, the AUC 0-inf on Day 2 decreased from 265 ng*hr / mL to 229 ng*hr / mL. However, Groups 6 and 7 performed better than Control 1 on Day 2 and the exposure was similar to or higher than that of the Control. Table 15-4: Azacitidine AUC for 20% Weight Gain Coated Mini Tablets at 75 / 25 Ratio 0-inf (Part 2 PK study) Table 15-5: Azacitidine C for 20% weight gain coated mini tablets at 75 / 25 ratio max Data (Part 2 PK study)

[0340] like Fig.15 and Fig.16 As shown in , azacitidine 20 mg mini-tablets coated with Surelease:pore former (80:20) at 15% weight gain extended the release of azacitidine to 90 minutes and mini-tablets coated with Surelease:pore former (75:25) at 20% weight gain extended the release of azacitidine to 120 minutes.

[0341] As shown in Table 15-2 and Table 15-4, based on the Day 2 azacitidine data, the AUC0-last of the 20 mg azacitidine dose from Groups 2 and 5 delivered as modified release was slightly lower than the azacitidine AUC in the control group, in which azacitidine was delivered as immediate release. However, for all other groups, Groups 3 and 6 (32 mg dose) and Groups 4 and 7 (40 mg dose), azacitidine exposure was higher compared to the AUC of the control group. Example 16: Pharmacokinetic (PK) study in monkeys using the combination of Example 4

[0342] In this study, azacitidine was delivered as delayed release at 5.3% enteric coating weight gain at two different dose levels of 20 mg and 40 mg. The cedaruridine dose was kept constant at 20 mg in all groups and delivered as immediate release. In the PK study, azacitidine was delivered as mini-tablets contained in HPMC capsules. Each mini-tablet contained 4 mg of azacitidine. The azacitidine mini-tablets were coated with Enteric coating, which is a 3-layer enteric coating that prevents drug release in the acid phase (pH 1.2), followed by rapid release at pH 6.8 in the buffer phase. The innermost layer is a seal coating followed by an intermediate coating containing an alkaline agent and a Final outer enteric coating of polymer. The L30-D55 polymer was used to provide an enteric coating on the azacitidine mini-tablets. PK studies

[0343] The PK dosing groups used in this study were as follows: Group 1 (control): 20 mg cedaruridine, immediate release + 20 mg azacitidine, immediate release; Group 2: 20 mg cedaruridine, immediate release + 20 mg azacitidine, 5.3% Coated; Group 3: 20 mg cedaruridine, immediate release + 40 mg azacitidine, 5.3% Coating.

[0344] PK data in monkeys were collected on 5.3% coated mini-tablets at two different dose levels of azacitidine, 20 mg and 40 mg, and uncoated cedaruridine tablets. Control group 1 contained uncoated azacitidine and cedaruridine at a dose of 20 mg. The dosing groups are listed in Table 16-1. Table 16-1: Dosage group of coated small tablets

[0345] 5.3% polymer weight gain PK data for coated mini-tablets are presented in Fig.17 The results of the present invention are shown in Table 16-2 and Table 16-3. Five (5) mini-tablets or ten mini-tablets (10) were placed in a No. 1 HPMC-based capsule (Vcaps Plus) for PK study. The exposure of azacitidine in Group 2 was slightly lower on Day 2 compared to the control group. However, the exposure of the higher dose (40 mg dose) was higher compared to the control group. The higher azacitidine dose compensated for the exposure loss due to delayed release. Table 16-2: Azacitidine AUC 0-last Table 16-3: Azacitidine C max

[0346] Delivery of cedaruridine as an immediate release component in a fixed dose combination may improve azacitidine bioavailability and exposure. Based on the day 2 azacitidine data, the exposure of the Group 2 20 mg azacitidine dose delivered in delayed release was slightly lower than the azacitidine exposure of the control group, where azacitidine was delivered in immediate release. However, for Group 3 (40 mg dose), azacitidine exposure was higher compared to the control group. Having uncoated cedaruridine with pH-sensitive coated azacitidine in an immediate release capsule achieves exposure similar to uncoated azacitidine, but may require higher doses. Example 17: Pharmacokinetic (PK) study in monkeys using the combination of Example 6

[0347] For this study, 20 mg of azacitidine was delivered as delayed release at 4.0% enteric coating weight gain as described in Example 6. The cedaruridine dose was kept constant at 20 mg in all groups and delivered as immediate release. In the PK study, azacitidine was delivered as mini-tablets contained in HPMC capsules. Each mini-tablet contained 4 mg of azacitidine as described in Example 6. The innermost layer was a seal coat followed by a Final external enteric coating of polymer. No intermediate coating was applied to the azacitidine mini-tablets in this round of PK studies. The L30-D55 polymer was used to provide an enteric coating on the azacitidine mini-tablets. PK studies

[0348] The PK dosing groups used in this study were as follows: Group 1 (control): 20 mg cedaruridine, immediate release + 20 mg azacitidine, immediate release; Group 2: 20 mg cedaruridine, immediate release + 20 mg azacitidine, 4.0% Coating.

[0349] A total of four monkeys were given group 2 composition (20 mg cedaruridine, immediate release + 20 mg azacitidine, 4.0% Coating); and on days 8 and 9, group 1 composition (control, 20 mg cedar uridine, immediate release + 20 mg azacitidine, immediate release) was administered orally through a gavage tube into the stomach once a day. Blood samples (about 0.8 mL) were collected before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours after administration on day 1 and day 8 (first dosing day), and before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after administration on day 2 and day 9 (second dosing day). The PK data of the collected blood samples were evaluated. Table 17-1: Utilization 4.0% Dosing Groups for PK Study of L30-D-55 Coating Group Real-time release of sedacidine Azacitidine 1(Control) 20 mg 20mg (uncoated) 2 20mg 20mg(coated)

[0350] 4.0% polymer weight gain The PK data of the coated azacitidine mini-tablets are presented in Table 17-2. As shown in Table 17-2, the coated azacitidine mini-tablets delivered higher AUC and C at the same dose. max , because the absorption of azacitidine is delayed while the absorption of cedaruridine is not delayed. Table 17-2: Utilization 4.0% PK Data from L30-D-55 Coating Studies Example 18: Dissolution Study of FDC Capsules

[0351] Submit six capsule samples of Capsule 1 and six samples of Capsule 2 (described below) according to USP for delayed-release dosage forms. <711> Dissolution - Method A, perform dissolution testing. Table 18-1

[0352] Since the dissolution of enteric-coated capsules is pH-dependent, a two-stage dissolution is performed, wherein the acid stage is followed by the buffer stage. The dissolution method uses a USP type 1 basket apparatus operated at 75 rpm. The dissolution medium is 500 mL 0.1 N HCl maintained at 37°C. The capsule sample is closed with a spiral settler CAPWHT-XS and lowered into the dissolution vessel. The duration of the acid stage is 2 hours, wherein dissolution samples are pulled out at 30, 60, 90 and 120 minutes for analysis. At the end of the acid stage, the dissolution medium is switched to 50 mM phosphate buffer at pH 6.8, preheated at 37°C. Dissolution in the buffer stage continues for another 90 minutes, wherein dissolution samples are pulled out at 135, 150, 165, 180, 210 minutes for analysis. Infinite rotation is performed for another 15 minutes at 250 rpm. All dissolution tests are performed in USP apparatus 1. At the last time point called infinity, the rotation of the basket was increased from 75 rpm to 250 rpm in the dissolution medium.The amount of cedaruridine and azacitidine released was determined by reverse phase HPLC comparing the response of the dissolution samples with that of a reference standard (purchased from Shilpa Chemicals).

[0353] The HPLC conditions are as follows. Mobile phase A (MPA): 10 mM sodium phosphate buffer in water, pH 6.8. Mobile phase B (MPB): 50 / 50 (v / v) 10 mM sodium phosphate buffer in water, pH 6.8 / ACN. Column: X select CSH phenyl-hexyl 2.5um, 4.6x 75mm, P / N186006134. HPLC system: waters Alliance system. Diluent: 0.1N HCl and 50mM 10mM sodium phosphate buffer in water, pH 6.8. HPLC conditions: Column temperature: 23°C, injection volume: 10uL. 12 minutes from 98:2M.PA:MPB to 80:20M.PA:MPB to 98:2M.PA:MPB, gradient, flow rate 0.7ml / min.

[0354] Due to the instability of azacitidine in the dissolution medium across the physiological pH range, the major degradation products are also included in the amount of total dissolved azacitidine. Cedaruridine is degraded in the acid phase. Therefore, most of the degradation products of cedaruridine and its diastereomers are also included in the amount of total dissolved cedaruridine in the acid phase. In the buffer phase, cedaruridine degradation is minimized and only the cedaruridine peak is included in the amount of cedaruridine. The total dissolution reported includes the sum of the % dissolved in the acid phase and the buffer phase.

[0355] Fig.18A and Fig.18B The dissolution curves of cedaruridine and azacitidine are shown respectively. Fig.18A and Fig.18B As shown in , azacitidine and cedaruridine are slowly released in the acid phase and rapidly released in the buffer phase. Example 19: Bioequivalence of capsule formulations in cynomolgus monkeys

[0356] Male cynomolgus monkeys weighing 3 to 6 kg were used. A total of 12 animals were assigned to the study. The animals were dosed with tablets / capsules on Day 1 and Day 2 as shown in the table below. The dose level was 20 mg azacitidine and 20 mg cedaruridine per animal. The test tablets (Example 12) / capsules (Example 11) were administered orally. Table 19-1

[0357] Blood samples for plasma were collected as follows: before dosing (0), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after dosing on day 1; before dosing on day 2 (24 hours after dosing on day 1), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after dosing on day 2. Blood samples were collected via the cephalic vein or appropriate vein at the designed time points. The target 0.8 mL of blood was collected into a tube containing K2EDTA, which was pre-added with 20 μL of 0.4 mg / mL (tetrahydrouridine) THU.

[0358] Hematology was evaluated once per animal during the acclimation period (approximately 4 days prior to dosing day) and on day 9.

[0359] Table 19-2 and Table 19-3 show the data of the above experiments. Fig.19 The plasma exposure of cedaruridine in monkeys using the capsule of Example 17 is shown. Fig. 20 The plasma exposure of azacitidine in monkeys using the capsules of Example 17 is shown. Table 19-2 Table 19-3 Example 20: Clinical data using the combination of Example 6

[0360] For this study, 20 mg of azacitidine was delivered as delayed release at 4.0% enteric coating weight gain as described in Example 6. The cedaruridine dose was kept constant at 20 mg in all groups and delivered as immediate release. In the PK study, azacitidine was delivered as mini-tablets contained in HPMC capsules. Each mini-tablet contained 4 mg of azacitidine as described in Example 6. The innermost layer was a seal coat followed by a Final external enteric coating of polymer. No intermediate coating was applied to the azacitidine mini-tablets in this round of PK studies. The L30-D55 polymer was used to provide an enteric coating on the azacitidine mini-tablets.

[0361] Human subjects (n=6) were administered azacitidine. The PK dosing groups used in this study were as follows: Group 1: 60 mg subcutaneous azacitidine, 75 mg / m 2 Group 2: 60 mg oral azacitidine only (4.0% Group 3: 60 mg uncoated cedaruridine, oral + 60 mg azacitidine (4.0% Oral administration, once a day.

[0362] Human subjects (n=6) were dosed with Group 2 composition (oral azacitidine only) ("C1D-3") on Day -3 (before Day 1); Group 1 composition (subcutaneous) ("C1D1") on Day 1; and Group 3 composition ("C1D2"-"C1D7") on Days 2 to 7, once daily. Blood samples were collected before dosing and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 7, 9, and 24 hours after dosing. PK data of the collected blood samples were evaluated.

[0363] The azacitidine PK data are shown in Table 20-1. As shown in Table 20-1, co-administration with cedaruridin can increase the T of azacitidine. max , C max and AUC, indicating that immediate-release chiduridine increases the bioavailability of delayed-release azacitidine. In addition, oral administration of azacitidine and chiduridine showed a more stable extended release of azacitidine compared to subcutaneous administration of azacitidine. Table 20-1 ***

[0364] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0365] The invention illustratively described herein may be properly practiced in the absence of any elements, limitations, or other elements not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like should be read broadly and without limitation. In addition, the terms and expressions employed herein have been used as descriptive terms rather than limiting terms, and when such terms and expressions are used, there is no intention to exclude any equivalents of the features shown and described or portions thereof, but it should be recognized that various modifications are feasible within the scope of the claimed invention.

[0366] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety to the same extent as if each were individually incorporated by reference. In case of conflict, the present specification, including definitions, will control.

[0367] It should be understood that although the present disclosure has been described in conjunction with the above embodiments, the foregoing description and examples are intended to illustrate rather than limit the scope of the present invention. Other aspects, advantages and modifications within the scope of the present disclosure will be apparent to those skilled in the art.

Claims

1. A pharmaceutical dosage form comprising cedazuridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release.

2. The pharmaceutical dosage form according to claim 1, wherein the cedaruridine is formulated for immediate release.

3. The pharmaceutical dosage form according to claim 1 or 2, wherein the portion of the azacitidine formulated for modified release is formulated for enteric release.

4. The pharmaceutical dosage form according to any one of the preceding claims, wherein the portion of the azacitidine formulated for modified release is provided as mini-tablets comprising an enteric coating.

5. The pharmaceutical dosage form according to claim 4, wherein each azacitidine small tablet comprises: About 20% to 60% w / w azacitidine, wherein the weight percentage is relative to the total weight of the uncoated azacitidine mini-tablet; and One or more pharmaceutically acceptable excipients.

6. The pharmaceutical dosage form according to claim 5, wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of lactose monohydrate, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), croscarmellose sodium, silicon dioxide and magnesium stearate.

7. The pharmaceutical dosage form according to any one of claims 4 to 6, wherein the enteric coating comprises polymethacrylate or a copolymer thereof.

8. The pharmaceutical dosage form according to any one of claims 4 to 7, wherein the enteric coating is sensitive to pH changes in the intestine.

9. The pharmaceutical dosage form according to any one of claims 4 to 8, wherein each azacitidine mini-tablet further comprises a seal coating below the enteric coating.

10. The pharmaceutical dosage form according to claim 9, wherein the seal coat comprises hydroxypropylmethylcellulose (HPMC).

11. The pharmaceutical dosage form according to any one of the preceding claims, wherein the azacitidine is formulated for modified release and is provided as mini-tablets comprising an enteric coating.

12. The pharmaceutical dosage form according to any one of the preceding claims, wherein substantially all of the azacitidine is structured for extragastric release.

13. The pharmaceutical dosage form according to any one of the preceding claims, wherein the cedaruridine is uncoated and in the form of a mini-tablet, tablet, powder, blend, granules or pellets.

14. The pharmaceutical dosage form according to claim 13, wherein the uncoated minitablet, tablet, powder, blend, granules or pellets comprises about 10% to 40% w / w of cedaruridine.

15. A pharmaceutical dosage form comprising cedaruridine or a pharmaceutically acceptable salt thereof, and azacitidine or a pharmaceutically acceptable salt thereof, wherein: The cedaruridine is formulated for immediate release; and The azacitidine is formulated as a modified release mini-tablet comprising an enteric coating.

16. The pharmaceutical dosage form according to claim 15, wherein each azacitidine mini-tablet comprises about 20% to 50% w / w of azacitidine, wherein the weight percentage is relative to the weight of the uncoated azacitidine mini-tablet.

17. The pharmaceutical dosage form according to claim 15 or 16, wherein each azacitidine mini-tablet comprises an inner granule layer and an outer granule layer.

18. The pharmaceutical dosage form according to claim 17, wherein the inner layer of the granules comprises about 20% to 50% w / w azacitidine, about 10% to 60% w / w lactose monohydrate, about 2% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.5% to 10% w / w hydroxypropyl methylcellulose (HPMC), about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

19. The pharmaceutical dosage form according to claim 17 or 18, wherein the granular outer layer comprises about 1% to 60% w / w microcrystalline cellulose, about 1% to 10% w / w croscarmellose sodium, about 0.1% to 3% w / w silicon dioxide, and about 0.1% to 3% w / w magnesium stearate, wherein the weight percentages are relative to the total weight of the uncoated azacitidine mini-tablet.

20. The pharmaceutical dosage form according to any one of claims 15 to 19, wherein the enteric coating comprises polymethacrylate or a copolymer thereof.

21. The pharmaceutical dosage form according to any one of claims 15 to 20, wherein the enteric coating is sensitive to pH changes in the intestine.

22. The pharmaceutical dosage form according to any one of claims 15 to 21, wherein each azacitidine mini-tablet further comprises a seal coating.

23. The pharmaceutical dosage form according to claim 22, wherein the seal coat comprises hydroxypropylmethylcellulose (HPMC).

24. The pharmaceutical dosage form of any one of claims 15 to 23, comprising azacitidine and cedaruridine in a weight ratio of about 1:1 to about 1:

3.

25. The pharmaceutical dosage form according to any one of claims 15 to 24, comprising about 60 mg to 100 mg of azacitidine.

26. The pharmaceutical dosage form according to any one of claims 15 to 25, wherein the cedaruridine is in the form of an uncoated minitablet, tablet, powder, blend, granules or pellets.

27. The pharmaceutical dosage form according to claim 26, wherein the cedaruridine minitablet, tablet, powder, blend, granules or pellets comprises about 10% to 90% w / w cedaruridine, wherein the weight percentage is relative to the total weight of the cedaruridine uncoated minitablet, tablet, powder, blend, granules or pellets.

28. The pharmaceutical dosage form according to claim 26 or 27, wherein the cedaruridine minitablet, tablet, powder, blend, granules or pellets further comprises about one or more selected from the group consisting of: lactose monohydrate, hydroxypropyl methylcellulose (HPMC), croscarmellose sodium, silicon dioxide and magnesium stearate.

29. The pharmaceutical dosage form according to any one of claims 15 to 28, comprising about 5 mg to 60 mg of cedaruridine.

30. A capsule comprising the pharmaceutical dosage form according to any one of claims 1 to 29.

31. A capsule comprising: one or more azacitidine mini-tablets formulated for modified release, comprising azacitidine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable excipient, and an enteric coating; and An immediate-release cedaruridine in the form of an uncoated powder or blend, comprising cedaruridine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

32. A method of treating cancer in a patient comprising administering to a patient in need thereof a dosage form according to any one of claims 1 to 29 or a capsule according to claim 30 or 31.

33. The method of claim 32, wherein the cancer is leukemia.

34. The method of claim 32, wherein the cancer is selected from the group consisting of previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumor (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

35. The method of any one of claims 32 to 34, wherein the cancer is selected from the group consisting of previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

36. The method of any one of claims 32 to 35, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

37. The method of any one of claims 32 to 36, further comprising administering another therapeutic agent.

38. The method of claim 37, wherein the additional therapeutic agent is selected from one or more of the list consisting of: ADI-PEG 20, AMG-176, APG-115, APR-246, avelumab, bendamustine, bisantrene, brentuximab vedotin), capecitabine, CB-839, cisplatin, CS-01, cusatuzumab, cyclophosphamide, cytarabine, dasatinib, daunorubicin, DCLL9718S, decitabine, deferasirox, dexamethasone, durvalumab, eltrombopag, enasidenib, entinostat, entrectinib, enzalutamide, epacadostat, erythropoetin, etoposide, evorpacept, filgrastim, fludarabine phosphate), flumatinib, gemcitabine, gemtuzumabozogamicin), gilteritinib, GM-CSF, GSK2879552, HMPL-523, homoharringtonine, IBI188, ibrutinib, idarubicin, itacitinib, ivosidenib, jaktinib, KPT-8602, LDE255, lenalidomide, lirilumab, LP-108, magli magrolimab, MAX-40279, mitoxantrone, liposomal mitoxantrone, mocetinostat, moxifloxacin, nivolumab, olutasidenib, omacetaxine, oxaliplatin, paclitaxel, pembrolizumab, pevonedistat, pinostat metostat), pracinostat, quizartinib, Revlimid, rigosertib, rituximab, romidepsin, RP7214, S64315, S65487, sabatolimab, seclidemstat, selumetinib, siremadlin, sirolimus, SL-401, SNDX- 5613, sorafenib, talazoparib, tamibarotene, tolinapant, trastuzumab, tucidinostat, tyrosine kinase inhibitors, Uproleselan, Velcade, venetoclax, vincristine, visilizumab, vorinostat, and vosaroxin.

39. A pharmaceutical dosage form according to any one of claims 1 to 29 or a capsule according to claim 30 or 31 for use in the treatment of cancer.

40. A pharmaceutical dosage form according to any one of claims 1 to 29 or a capsule according to claim 30 or 31 for use in the manufacture of a medicament for the treatment of cancer.

41. The pharmaceutical dosage form or capsule for use according to claim 39 or 40, wherein the cancer is leukemia.

42. A pharmaceutical dosage form or capsule for use according to claim 39 or 40, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumor (MPNST) nerve cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

43. The pharmaceutical dosage form or capsule for use according to claims 39 to 42, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

44. The pharmaceutical dosage form or capsule for use according to claims 39 to 43, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.

45. Use of a pharmaceutical dosage form according to any one of claims 1 to 29 or a capsule according to claim 30 or 31 for treating cancer.

46. ​​Use of a pharmaceutical dosage form according to any one of claims 1 to 29 or a capsule according to claim 30 or 31 for the manufacture of a medicament for the treatment of cancer.

47. The use according to claim 45 or 46, wherein the cancer is leukemia.

48. The method of claim 45 or 46, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), malignant peripheral nerve sheath tumors (MPNST), neurological cancer, breast cancer, hormone receptor positive tumors, head and neck cancer, primary central chondrosarcoma, myeloproliferative neoplasms (MPN), relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Hodgkin's lymphoma, relapsed / refractory multiple myeloma (RRMM), metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC) and lung cancer.

49. The use according to any one of claims 45 to 48, wherein the cancer is selected from previously treated or untreated primary or secondary myelodysplastic syndrome (MDS), and previously treated or untreated primary or secondary chronic myelomonocytic leukemia (CMML).

50. The use according to any one of claims 45 to 49, wherein the cancer is associated with refractory anemia, refractory anemia with ring sideroblasts, or refractory anemia with increased blasts.